IRIS AperTO

UNIVERSITÀ DEGLI STUDI DI TORINO

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Endocytosis in the context-dependent regulation of individual and collective cell properties

This is the author's manuscript

Original Citation:

Availability:

This version is available http://hdl.handle.net/2318/1795208 since 2021-07-28T12:30:12Z

Published version:

DOI:10.1038/s41580-021-00375-5

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

16 July 2024

Endocytosis in context-dependent regulation of individual and collective cell properties

Sara Sigismund[1,2], Letizia Lanzetti[3,4], Giorgio Scita[2,5], Pier Paolo Di Fiore[1,2*]

[1] IEO, European Institute of Oncology IRCCS, Milan, Italy
[2] Department of Oncology and Haemato-Oncology, Università degli Studi di Milano, Milan Italy
[3] Department of Oncology, University of Torino Medical School, Italy
[4] Candiolo Cancer Institute, FPO - IRCCS, Candiolo, Torino, Italy
[5] IFOM, the FIRC Institute of Molecular Oncology, Milan, Italy
* Corresponding author pierpaolo.difiore@ieo.it

Author contributions
The authors contributed equally to all aspects of the article.

Abstract

Endocytosis allows cells to transport particles and molecules across the plasma membrane. In addition, it is involved in the termination of signalling through receptor downmodulation and degradation. This "traditional" outlook has been substantially modified, in recent years, by discoveries that endocytosis and subsequent trafficking routes have a profound impact on the positive regulation and propagation of signals, being key for spatio-temporal regulation of signal transmission in cells. Accordingly, endocytosis and membrane traffic regulate virtually every aspect of cell physiology, and are frequently subverted in pathological conditions. Two key aspects of endocytic control over signalling are coming into focus: context-dependency and long-range effects. First, endocytic-regulated outputs are not stereotyped, but heavily dependent on cell-specific regulation of endocytic networks. Second, endocytic regulation has impact not only on individual cells, but also on the behaviour of cellular collectives. Herein, we will discuss recent advancements in these areas, highlighting how endocytic trafficking impacts complex cell properties, including cell polarity and collective cell migration, and the relevance of these mechanisms to disease, in particular cancer.

[H1] Introduction

Endocytosis is used by cells to internalize various types of molecules, including nutrients, and fluids, which could not otherwise pass through the plasma membrane[1,2]. While this has probably represented the initial driving force behind its emergence in evolution, the system has been exploited to actively regulate various forms of communication within the cell and between the cell and its environment. Signalling receptors, for instance, are internalized upon engagement by cognate ligands and frequently targeted for degradation in the lysosome, resulting in long-term signalling attenuation[3,4]. In addition, regardless of their interaction with extracellular moieties, many surface-resident molecules (mostly, but not exclusively, proteins) are

48 internalized and either degraded or recycled back to the cell surface, thereby providing
49 a mechanism through which the cell controls and adjusts its repertoire of plasma
50 membrane-resident molecules for various functional purposes. Yet, these are only
51 particular facets of endocytosis, whose impact on cellular homeostasis appears much
52 wider (see Supplementary Table 1).

53 A modern view of endocytic trafficking is that of a "vast program, deeply engrained
54 in the cellular masterplan and inextricably intertwined with signaling, which
55 constitutes the major communication infrastructure in the cell"[1]. At the individual cell
56 level, for instance, endosomes represent major signalling stations. This is embodied in
57 the concept of the "signalling endosome": a platform capable of sustaining signalling
58 by numerous mechanisms, including assembly of endosome-specific signalling
59 complexes, crosstalk, regulation of signal persistence in intracellular compartments,
60 and signal computing and resolution in time and space[5]. Endocytosis also controls the
61 execution of polarized cell functions through the redistribution of surface molecules
62 towards sites of polarized activities. In this case, fast and site-directed redistribution of
63 membrane proteins is not achieved by planar diffusion on the plasma membrane, but
64 rather by cycles of endocytosis and directed recycling[6-9].

65 Although these activities are largely pertinent to the workings of individual cells, it
66 is becoming increasingly clear that also cellular collectives are controlled by
67 endocytosis. This is remarkable, as it entails that endocytic events occurring on the
68 level of a single cell must be synchronized, frequently spanning a distance of hundreds
69 of cells, to contribute to a coordinated behaviour[10-13].

70 Mechanistically, endocytosis has long been considered a rather stereotyped
71 process, irrespective of the cell type and (to some extent) of the transported cargo.
72 This vision started to change with the realization that clathrin-coated pits, responsible
73 for clathrin-mediated endocytosis (CME), have varying compositions and contain a
74 plethora of non-obligatory components that confer specificity to the uptake process. In
75 addition, a wealth of non-clathrin endocytosis (NCE) routes exist, which also exhibit
76 context specificity, being present only in certain cell types[2,15,16]. This heterogeneity in
77 endocytic mechanisms is reflected in differences in effector functions in cells, both at
78 the individual and the collective cellular level, which increasingly appear to depend on
79 the varying "endocytic landscapes" of different cell types. With this expression, we
80 mean the varying cellular composition in endocytic and trafficking proteins that can
81 determine the presence or absence of a certain endocytic route and/or confer a
82 different cargo specificity of the same endocytic route in different cells. In turn, this
83 may determine diverse biological outcomes in response to the same signalling input,
84 as a function of the cellular endocytic context.

85 Given the pervasive nature of endocytosis and its emerging roles in the control of
86 virtually every cellular phenotype (Supplementary Table 1), it is not surprising that its
87 subversion is relevant to human pathologies[1,17,18]. As one example, in cancer, the
88 context-dependency of endocytic control over signalling might have a major role in the
89 migratory/invasive phenotype. Indeed, endocytic pathways seem to be preferentially
90 involved in the acquisition of pro-metastatic traits *vs*. other tumor properties[6,18] (see
91 Supplementary Tables 2 and 3).

92 In this Review, we discuss the pleiotropic roles of endocytosis in cell regulation and
93 the importance of these mechanisms in physiology and pathology, especially cancer.
94 Many of these facets of endocytosis have been excellently reviewed elsewhere[5-7,10-13].

95 Herein, we will concentrate on an emerging trait: that of context-dependency of
96 endocytic regulation, with respect to different cell types and different stimuli they are
97 exposed to. We will also highlight the emerging view that endocytic trafficking,
98 although occurring at the single-cell level, has an impact on tissue-wide properties and
99 behaviours, such as tissue polarity and collective cell migration.
100
101 **[H1] Endocytic regulation in context**
102
103 In this section, we will use paradigmatic examples to illustrate how the greater context
104 – encompassing type of cargo as well as cell type and expression of proteins
105 comprising endocytic machinery – in which endocytosis operates influences its impact
106 on cell function in physiology and cancer. We will concentrate predominantly on the
107 regulation of signalling by receptor tyrosine kinases (RTKs) and G protein-coupled
108 receptors (GPCRs). For discussions on the impact of endocytic routes on intracellular
109 communication mediated by membrane contact sites[19-21], on endocytosis in neuronal
110 communication and synaptic function[22-24], and on the trafficking of adhesion
111 molecules, such as integrins and cadherins[25-27], we refer the reader to several
112 exhaustive reviews.
113
114 **[H2] Differential regulation of signalling by distinct clathrin-coated structures.**
115 Different types of clathrin-coated structures exist at the surface of mammalian cells.
116 These include dynamic curved clathrin-coated pits that are heterogeneous in
117 dimension, dynamics and composition and are responsible for constitutive and ligand-
118 induced CME of different cargoes (Figure 1) as well as long-lived large flat clathrin
119 lattices, also known as coated plaques[28-33], which act as signalling and adhesion
120 platforms[34], in addition to other functions (Box 1).
121 CME is characterized by a core of molecular components, prominently including:
122 clathrin; its main adaptor, adaptor protein 2 (AP2), which bridges cargoes to
123 clathrin[35,36]; and the GTPase, dynamin, responsible for endocytic vesicle fission[37,38] (see
124 example in Figure 1a). Depending on the cellular context and the type of cargo, other
125 adaptors — such as DAB2, ARH, epsins, EPS15 and EPS15L1 as well as arrestins —can
126 link cargoes to the clathrin machinery, producing clathrin-coated pits with varying
127 characteristics[14,36,39] (see example in Figure 1b). In addition, AP2 levels are regulated in
128 a cell context-dependent manner, impinging on CME dynamics[40] and on fate(s) and
129 function(s) of signalling receptors (see below). Thus, the view that clathrin-coated pits
130 represent a uniform population is now outdated; it is now evident that distinct
131 clathrin-coated pits exist, with differential roles in the control of receptor fate and
132 signalling[28].
133 This is exemplified by the regulated endocytosis of GPCRs, which occurs
134 preferentially through subsets of distinct clathrin-coated pits characterized by: the
135 engagement of specific adaptors (such as β-arrestins)[41]; specific regulation, (such as
136 receptor ubiquitylation)[41]; increased surface residence time/slow internalization rates
137 (achieved by receptor–actin cytoskeleton interactions) (Figure 1c)[42-44]. GPCR
138 recruitment to specific subsets of clathrin-coated pits and cargo (ligand-bound GPCRs)-
139 dependent control of clathrin-coated pit dynamics and composition, are thought to
140 reduce competition with other CME cargoes, allowing the generation of clathrin-
141 coated pits with specialized functions[42]. Interestingly, β-arrestin-mediated CME varies

142 depending on the type of GPCR that is activated, as exemplified by the β-subfamily of
143 adrenergic receptors (AR). At variance with the other family members, the β1-AR is
144 endocytosis-incompetent, meaning it is not internalized, yet, is still able to induce β-
145 arrestin accumulation and signalling in clathrin-coated pits[45-47]. Although the molecular
146 mechanisms responsible for this accumulation and activation of β-arrestin are not
147 completely elucidated, computational simulations suggest that the active
148 conformation of β-arrestin is stabilized by binding to the receptor tail and persists even
149 after detachment from the receptor; this conformational change renders β-arrestin
150 competent for binding to clathrin and AP2[47].

151 Similar to GPCRs, the epidermal growth factor receptor (EGFR) is also internalized
152 through distinct classes of clathrin-coated pits, distinguished by the presence or
153 absence of AP2 (Figure 1d), which differently regulate EGFR recycling/degradation and
154 thereby signalling, in a context-specific fashion (*e.g.*, fibroblasts *vs*. epithelial cells),
155 depending on the type of internalizing clathrin-coated pit (AP2-proficient or AP2-
156 less)[48-51]. Specialized and context-specific functions of clathrin-coated pits also appear
157 to be conferred by the different members of the epsin family of endocytic adaptor
158 proteins [52-54]. Epsin1 (EPN1) and EPN2 are ubiquitously expressed and are implicated in
159 the CME of several plasma membrane receptors, such as the aforementioned EGFR, as
160 well as vascular endothelial growth factor receptors (VEGFR), NOTCH and WNT
161 receptors[48,55-60]. By contrast, EPN3 shows a more restricted pattern of expression,
162 suggesting cell-specific functions[52,61]. Indeed, EPN3 has a selective role in the
163 regulation of E-cadherin (CDH1) endocytosis and turnover and, when
164 amplified/overexpressed, contributes to breast cancer development through the
165 induction of a partial epithelial- mesenchymal transition (EMT) state (see also
166 subsection Endocytosis and EMT below)[53].

167 Different dynamin isoforms also mark distinct types of clathrin-coated pits.
168 Dynamin1 (DYN1) has traditionally been viewed as neuronal-specific and involved in
169 synaptic vesicle recycling, where its activity is regulated through phosphorylation–
170 dephosphorylation cycles[62]. By contrast, dynamin2 (DYN2) is constitutively active and
171 responsible for ubiquitous and constitutive endocytosis in all cell types[62-66]. Increasing
172 evidence, however, indicates that DYN1 can regulate CME also in non-neuronal cells,
173 and is selectively recruited to subsets of clathrin-coated pits, distinct to those
174 containing DYN2 (refs. [66,67]). In these cells, similarly to neurons, DYN1 is kept inactive
175 through GSK3β-dependent phosphorylation[36,65,68]. This inhibition is released upon EGF
176 stimulation, leading to DYN1 activation. Thus, at variance with DYN2, DYN1 appears to
177 be selectively activated by specific ligands. Interestingly, dynamins are deregulated in
178 cancer[69]. DYN2 overexpression promotes invasiveness in different cancers, including
179 hepatocellular carcinoma, prostate and pancreatic cancer[70-72]. DYN1 is aberrantly
180 activated in non-small cell lung cancer where GSK3β function is inhibited, leading to
181 dysregulated CME of the EGFR and to the acquisition of migratory/invasive properties
182 (Figure 1e)[66,73]. In addition, DYN1 activation, via calcineurin-dependent
183 dephosphorylation, upregulates endocytosis of death receptors, inhibiting apoptosis
184 and contributing to cancer cell survival[74].

185 Thus, the specialization of the machinery employed in clathrin-coated pits — driven
186 by the engagement of different cargoes, adaptor repertoire and cellular context (such
187 as expression of particular components of the machinery or their differential
188 regulation) — can impinge on cell behaviour in physiology and in cancer.

[H2] Context-dependent regulation of signalling by NCE and integration of outputs.

NCE comprises several internalization mechanisms differing in morphology of the internalizing structures at the plasma membrane, machinery, cargo and regulation[2,15,16]. Herein, we will not cover endocytosis through caveolae and refer the reader to extensive reviews on the subject[75,76].

The existence of so many NCE mechanisms might be, in part, due to inaccurate classification, as historically they were defined solely on the basis of clathrin-independence. Indeed – as we gain a deeper understanding of the specific features of NCE mechanisms, their overlapping characteristics and dependency on cellular context – it is becoming clear that some of them might represent “variations on a theme”, rather than truly distinct processes (Figure 2).

CLIC/GEEC (clathrin-independent carrier/GPI-anchored protein-enriched early endosomal compartment) [77-79] is an NCE mechanism of central relevance: it relies on pleomorphic tubular endocytic intermediates and displays high endocytic capacity (Figure 2a)[2], rendering it suitable for mediating large plasma membrane rearrangements. CLIC/GEEC is thus implicated in plasma membrane turnover during cell spreading and migration[80] and in the regulation of membrane tension in adherent cells[81]. Indeed, upon a sudden reduction in plasma membrane tension, CLIC/GEEC is transiently activated to remove excess “floppy” membrane invaginations, thereby restoring the initial plasma membrane tensile state[79,81]. The opposite is also true: perturbation of CLIC/GEEC directly decreases plasma membrane tension. In this circuitry, vinculin acts as the CLIC/GEEC-sensing mechanotransducer at focal adhesions[81,82]. The mechanical buffering role of CLIC/GEEC differs from that of caveolae, which passively buffer the increase in tension also in non-adherent cells and seem to be critical for anchorage-independent growth[83]. An interesting view of CLIC/GEEC is that of a prototype coatless NCE mechanism mediated by a conserved core of molecular components, while other NCE routes might represent specialized variants. For instance, fast endophilin-mediated endocytosis (FEME)[84] has many commonalities with CLIC/GEEC[85], but differs in that it is strictly regulated by receptor activation and displays rapid kinetics (Figure 2b)[84].

Another NCE mechanism, crucial to the fate and signalling of its cargo, is EGFR-NCE[56,86]. This route internalizes the EGFR at high EGF doses in cellular contexts distinct from those where FEME and CLIC/GEEC are active (Figure 2c)[86,87]. EGFR-NCE relies on contacts between the plasma membrane and the endoplasmic reticulum (ER), which might generate the pulling force for the formation of plasma membrane tubular invaginations. These contacts are also necessary for localized Ca^{2+} release from the ER, required for NCE vesicle fission[87]. Since this route targets the EGFR to degradation and ultimately restricts its downstream signalling[86,87], it could represent a tumour suppressor pathway, as EGFR is commonly upregulated in cancer[88,89]**.** Of note, a preferential degradative fate for internalized receptors might characterize other NCE mechanisms, as shown – for instance – in the case of the β and γ subunits of the IL2 receptor (Figure 2d)[90,91]. However, it is worth pointing out that the degradative route does not necessarily preclude signalling from the internalized receptor, as shown for EGFR-NCE (see subsection Endomembrane dynamics controls collective motion).

Similarly to the EGFR, other RTKs are internalized via different endocytic routes. This is the case of MET (the receptor for hepatocyte growth factor), PDGFR (platelet-

236 derived growth factor receptor), VEGFR2, IGF1R (insulin-like growth factor 1 receptor)
237 and NGFR (nerve growth factor receptor)[2,85]. For instance, IGF1R enters the cell via
238 CME or through caveolae depending on the dose of IGF1 (refs. [92,93]). Similarly,
239 depending on ligand concentrations, PDGFRB switches between CME and the
240 CLIC/GEEC pathway[94-96]. These RTKs are also internalized via FEME[84]. Also in these
241 cases, the choice of entry route might specify the signalling outcome, as exemplified by
242 the VEGFR2 system[84,97-99]. Postnatal retinal angiogenesis is controlled by spatially
243 regulated VEGFR2 endocytosis: mature vessels in the central retina display slow
244 VEGFR2 endocytosis, while, at the edge of the growing vasculature, tip cells show high
245 internalization rate, promoting the extension of the vessel network. In these cells,
246 VEGFR2 is internalized both via ephrin-B2/DAB2-mediated CME and endophilin-A2-
247 mediated NCE (resembling the FEME pathway). Consequently, CME of VEGFR2
248 promotes ERK signalling and vessel sprouting, whereas NCE regulates the signaling
249 effector PAK, front–rear polarization, and migration of tip cells[98-100].
250 Macropinocytosis is a form of bulk NCE, which internalizes extracellular fluids and
251 macromolecules in large heterogeneous vesicles (Figure 2e)[101]. In mammalian cells, it
252 displays remarkable cell-specific variations in terms of molecular mechanism, fate of
253 the macropinosomes (recycled or degraded), and regulation[102]. In macrophages and
254 immature dendritic cells, macropinocytosis is constitutively active and critical for
255 antigen presentation[102]. Conversely, epithelial cells show barely detectable levels of
256 macropinocytosis in normal growing conditions. However, micropinocytosis is induced
257 in epithelia by growth factors and pathogens, and is upregulated in cancer[102] by
258 activation of oncogenes, such as RAS and SRC[103-105]. Under nutrient-deprived
259 conditions, when the supply from the vasculature is insufficient, cancer cells can
260 scavenge nutrients (mainly albumin) from the extracellular environment by
261 macropinocytosis[106]. This provides a sufficient intracellular pool of amino acids (in
262 particular glutamine) to meet the demands for energy production and nucleotide
263 biosynthesis.
264 Through macropinocytosis, cancer cells can also internalize necrotic debris (which
265 probably provides a higher quality source of nutrients), in a process called
266 necrocytosis. This debris is degraded, providing amino acids, fatty acids, sugars and
267 nucleotides used in anabolic pathways[107,108]. In prostate cancer cells, in nutrient
268 deprivation conditions, necrocytosis is stimulated by PTEN loss, which cooperates with
269 active AMPK to stimulate RAC1 -dependent macropinocytosis. AMPK is also required
270 for RAS-driven macropinocytosis under nutrient restriction, indicating a general role of
271 this kinase in macropinosome formation[107]. Context is again at play, since cancer cell
272 lines displaying similar oncogenic alterations vary in the extent and modality
273 (constitutive or inducible) of necrocytosis[108]. Importantly, necrocytosis promotes
274 therapy resistance as it relieves stress induced by drugs targeting anabolic
275 pathways[108]; thus, its inhibition could be exploited to target therapy resistant
276 tumours[109].
277
278 **[H2] Context-dependent role of endosomes in signalling and cellular responses.**
279 Although the activity of signalling receptors starts at the plasma membrane, it is now
280 abundantly clear that it persists in the various endocytic routes. In particular,
281 endosomes are critical signalling 'stations' that: sustain signalling originating from the
282 plasma membrane; are able to direct signalling through the recruitment of specific

effector molecules; create membrane microdomains where receptors are sequestered, upon specific post-translational modifications, and sorted to their final fate, thereby regulating signalling outcomes[5,110]. The centrality of endosomes as signalling platforms has been established for several signalling pathways in physiology and in cancer[1,5]. Here, we will focus on examples relevant to the idea of context-dependency.

GPCRs induce signalling from multiple cellular locations[111,112]. At the plasma membrane, GPCRs signal through the so-called “canonical pathway”, leading to adenylyl cyclase activation and cAMP production. Upon prolonged ligand exposure, β-arrestins bind to phosphorylated GPCRs, extinguishing the signals and inducing receptor internalization (Figure 1c). β-arrestins also promote “non-canonical” GPCR signalling by their scaffolding function and activation of signalling pathways centred on ERK, p38 and JNK[111]. Canonical and non-canonical GPCR signalling can occur at the plasma membrane and from the endosomal station[111,112], in a context-dependent manner (see subsection Differential regulation of signalling by distinct clathrin-coated structures) and further demonstrated by in vivo studies of *Drosophila melanogaster* gastrulation, where tissue level regulation of GPCR endocytosis by specific factors and the dynamic partitioning of active receptors in different plasma membrane compartments, *i.e.,* flat plasma membrane or invaginations, determine different patterns of myosin II activation in mesodermal *vs*. ectodermal cells leading to differential tissue specification[113,114]. In addition, for some GPCRs, signalling was shown to be transmitted also from the Golgi compartment[115,116] and from the nucleus[117], regulating pathways distinct from those activated at the plasma membrane. Finally, adenylyl cyclases themselves are regulated by trafficking and localize to different cellular compartments, thus representing an additional variable for the diversification of GPCR signalling[118-121]. The emerging picture is that of a complex pattern of regulation, orchestrated by “localization biases” (*i.e*., the cellular compartment from which the signal originates) and dependent on cellular context, where different membrane compositions and specific sets of adaptors/interactors determine biological output[122-124]. This has enormous therapeutic implications. GPCRs are easily druggable: approximately 35% of all approved drugs are directed against them[125]. Further advances in this field will largely depend on knowledge of spatial resolution of GPCR signalling, to design more effective drugs with localization bias that would target a specific signalling output[126]. For instance, endosomal signalling of GPCRs has been involved in chronic inflammation and pain, and revealed to be an effective therapeutic target through the use of endosomally-directed GPCR antagonists[127-129]. These types of drugs may also benefit cancer patients; this is a particularly urgent need since, despite extensive knowledge of altered GPCR signalling[130-132] in tumours, only a few anti-GPCR drugs are approved for therapy in this disease[133].

Similarly, EGFR signalling is transmitted and regulated both at the plasma membrane and from endosomes, where specific signalling platforms are assembled to sustain and/or specify the signalling output (Figure 2c)[1,5]. A clear example of this regulation is represented by ERK1/2 signalling, which is involved in multiple cellular outputs, including proliferation, migration and survival[134,135]. Waves of ERK activation were observed in epithelial cell sheets during wound healing[136] and their propagation serves as a directional cue for collective cell migration[137]. This might be due to endosome-originated signals, as sustained ERK1/2 activation from endosomes is

330 necessary to exert a productive collective migratory response in breast epithelial
331 cells[7,138]. Of note, in this instance, the EGFR is internalized through NCE-EGFR, a cell-
332 specific, and hence context-dependent, process (see subsection Context-dependent
333 regulation of signalling by NCE and integration of outputs). We will further discuss
334 these issues later (subsection Endomembrane dynamics controls collective motion).
335 In addition to the recruitment of endosomal signalling effectors, the modulation of
336 early endosome homotypic fusion represents another mechanism that regulates EGFR
337 signal amplitude and duration, and thereby cellular response. This is achieved by the
338 direct regulation of the fusion–fission machinery exerted by active EGFRs, leading to
339 modulation of the number of endosomes, which may act as quanta signalling
340 platforms that contain a pre-set number of activated receptors, thereby ultimately
341 determining context-dependent programmes driving cell proliferation versus cell
342 differentiation[139].
343 Finally, it is well established that endosomal membrane compartmentalization, that
344 is, the specification of specialized membrane microdomains on the limiting membrane
345 of endosomes, has a crucial role in receptor sorting and fate at endosomal signalling
346 stations[110,140] with impact on the duration and specificity of signalling outputs. RAB
347 GTPases are pivotal in this process, as they contribute to the definition of endosomal
348 microdomains[141,142]. An example of how RABs define endosomal microdomains was
349 elucidated studying RAB5 (refs. [141,143]): active RAB5, initially recruited to endosomes,
350 can further recruit its own GEF, creating a local, positive feedback loop of activation. In
351 addition, RAB5 directly modifies the local lipid environment stabilizing its own
352 membrane recruitment, thus providing another level of positive feedback regulation
353 that determines its patterning[144-149]. Notably, three highly conserved RAB5-encoding
354 genes exist, which share biochemical and biological activity. However, they can also
355 display specific functions depending on the cell context (as a function of their relative
356 levels of expression[150]), signalling pathways that they impinge upon, and possibly
357 subcellular localization[151-153]. Additionally, only the expression of RAB5A, but not
358 RAB5B or RAB5C, is elevated in breast carcinomas and is capable of reawakening cell
359 locomotion of jammed epithelial monolayers of breast tissue cells by differentially
360 impacting on endosomal signalling (see section Endomembrane dynamics controls
361 collective motion below).
362 A similar mechanism has been described for specification of endosomal
363 microdomains by the small GTPase CDC42 (refs. [154,155]) and for organization of plasma
364 membrane microdomains by K-RAS[156]. Such non-linear dynamics of recruitment and
365 activation are typical of self-organizing systems that form spatial patterns on
366 membranes[157], possibly representing a general mechanism for spatial organization of
367 GTPases inside cells and for their role in generating membrane microdomains critical
368 for receptor fate and sorting along the endocytic pathway[158].
369
370 **[H1] Endocytosis in tissue morphogenesis**
371
372 In this and in the following section, we will discuss the role of endocytosis and
373 endocytic trafficking in the control of epithelial cellular collectives. In this section, we
374 will highlight emerging principles relative to the role of endocytosis in tissue
375 organization by focusing on the establishment of apical-basal cell polarity during

376 lumenogenesis of epithelial sheets, and tissue extension and cell shape morphogenesis
377 in embryo development and adult epithelia.
378

379 **[H2] Polarized transport controls apical-basal cell polarity and lumenogenesis**

380 A defining feature of epithelial and glandular tissues is a pronounced apical–basal
381 asymmetry, which is important for establishing barrier function, polarized
382 transport[159,160], and successful lumenogenesis/tubulogenesis that gives these tissues
383 their shape[161,162]. Failure of these mechanisms results in altered epithelial function,
384 dysmorphologies and malignant transformation[163].

385 Directed membrane trafficking is critical for the polarized distribution of molecules
386 in the cell and for the generation of specialized membranous domains in individual
387 epithelial cells, but also for the coordination of epithelial polarization during lumen
388 formation and the morphogenesis of glandular tissues[160-162]. There is extensive
389 interplay between membrane trafficking and cell polarity (illustrated in Figure 3),
390 whereby epithelial polarization involves not only the formation of apical and
391 basolateral domains, but a whole topological re-organization of intracellular trafficking
392 pathways along the apical-basal axis.

393 Two major membrane routes are used to establish apical-basal polarity in individual
394 cells[164]. The first one involves recycling of polarity molecules from the plasma
395 membrane followed by their sorting and targeted delivery to a polarized surface. The
396 second one involves regulated trafficking of newly synthesized polarity determinants.
397 Both of these routes are accomplished by polarized membrane trafficking regulated by
398 RAB GTPases[165], which are key regulators of membrane trafficking also in non-
399 polarized cells; however, of the ~70 mammalian RABs, only a dozen has been
400 specifically implicated in regulating apical-basal cell polarity[166]. Furthermore, while
401 some RABs operate regardless of environmental conditions, others control apical-basal
402 cell polarity solely during 3D morphogenetic events, but not in 2D, indicating context-
403 dependency[166].

404 Central to the establishment and maintenance of apical-basal polarity is the correct
405 topological distribution of membrane-associated apical-basal cell polarity complexes
406 (Supplementary Box 1) and lipid domains, organelles, and cytoskeletal structures[167]
407 (Figure 3). A detailed description of apical-basal cell polarity complexes, their
408 interaction with trafficking components, and their routes, is outside the scope of this
409 review, but several excellent reviews on this topic are available[168-170].

410 How these events, occurring on a cellular level, orchestrate the morphogenesis of
411 tube-shaped and sac-shaped structures is the object of intense scrutiny. A model
412 system that reproduces the early steps of apical lumen formation and expansion is
413 MDCK cells in 3D culture[160,171]. Following cell division, individual MDCK cells remain
414 connected by a midbody, which serves as the spatial instructive cue for the creation of
415 an apical membrane initiation site, thus establishing the location of the nascent lumen
416 (Figure 4a). This process involves multiple trafficking steps. The first establishes the
417 structural identity of the apical membrane initiation site through the coordination and
418 re-organization of microtubules and branched actin filaments, via RAC1 GTPase-WAVE
419 pathway and the adhesion protein, cingulin. This latter protein binds the central
420 spindle microtubules and is recruited to the apical membrane initiation site via a direct
421 interaction with the midbody and the tight junction protein, ZO1. Cingulin then can
422 activate Arp2/3 complex to promote branched polymerization, which in turn recruits

423 more ZO1 — and consequently more cingulin — installing a positive feedforward loop
424 critical for reinforcing the apical localization of these proteins[172]. Cingulin also serves
425 as a tethering platform for the anchoring of apical endosomal vesicles by directly
426 interacting with FIP5, a RAB11-interacting protein[172,173] (Figure 4b). Consequently,
427 transmembrane proteins, such as podocalyxin (a classical apical marker) and Crumbs
428 polarity complex— which undergo transcytosis from the extracellular matrix abutting
429 surface to the apical membrane initiation site via RAB11-marked endo/exocytic
430 structures (which are most likely also positive for RAB8; see discussion in the following
431 paragraph) — can be hooked to the apical membrane initiation site through
432 interaction with cingulin and FIP5. Alternatively, association of apical polarity proteins
433 with the apical membrane initiation site could occur through binding to RAB35, which
434 in addition to cingulin has been proposed to act as an anchoring platform for polarity
435 determinants[171,174]. Although the exact molecular role of RAB35 is still debated, there
436 is a consensus that its function is important for the correct transport of apical and
437 basolateral determinants[166,175].
438 Additionally, RAB11 can also activate RAB8 through the GEF RAB3IP (aka Rabin8) on
439 Rab11 and RAB8 double-positive endosomes. Both RAB8 and RAB11 can I then recruit
440 myosin motor, MYO5B and the EXOC6 (aka Sec15A) exocyst subunit in order to
441 transport recycling vesicles that carry critical polarity determinants to the apical
442 membrane initiation site[176], and they also interact with EXOC5 (aka Sec10) at the apical
443 membrane initiation site to promote vesicle docking (Fig. 4B, inset)[171].
444 Finally, apical membrane initiation site is characterized by a unique phospholipid
445 composition, being enriched in di-phosphorylated phospholipids, including PI(3,4)P2
446 (ref. [177]) and PI(4,5)P2 (ref. [178]). This lipid environment is critical for the asymmetric
447 recruitment of annexin-2 and of the CDC42 apical polarity complex, which is in turn
448 capable of binding key apical polarity determinants, PAR3 and PAR6[178]. These lipids
449 also ensure the correct localization and function of membrane-curvature sensor
450 proteins. One such protein, IRSP53 (aka BAIAP2), binds to PI(4,5)P2-rich membranes. In
451 the early stages of cyst formation, IRSP53 re-localizes from the plasma membrane to
452 endosomal structures and to the apical membrane initiation site, where, through its I-
453 BAR domain (which binds to negatively curved membranes), it ensures the integrity
454 and shape of the opposing membranes of the two neighbouring cells for correct lumen
455 generation. Loss of IRSP53 results in the formation of aberrant cytoplasmic bridges
456 that interconnect adjacent cells and interrupt the continuity of the nascent lumen,
457 yielding aberrant multiple lumens[179].
458 It is still unclear how, after the establishment of the apical membrane initiation site,
459 a lumen develops and expands. It is likely that a balance of forces between tensile
460 junctional elements and cell–substrate adhesion, contributes to the position and shape
461 of the de novo lumen[180,181]. Additionally, lumen opening might be driven by: reduced
462 actomyosin contractility at adherens junctions, which allows fluctuation of the
463 membrane at the interface between two adjacent cells; and/or by increased
464 intraluminal hydrostatic pressure, which follows the establishment of tight junctions
465 and the polarized flux of water through ion channels (Figure 4c). Notably, as the lumen
466 inflates the cell volume decreases, suggesting that the system is isochoric and
467 proceeds through volume conservation between the cells and the luminal space[182].
468 An invariable feature of carcinomas is the loss of epithelial stereotypical
469 architecture. Observations in *D. melanogaster* identified polarity regulators as tumour

470 suppressors. By contrast, studies in mammals suggest oncogenic dominant roles of
471 these proteins[183]. A number of polarity determinants – including PARD6B, SCRIB, PRKCI
472 and DLGs – are amplified or display aberrant cellular distribution in cancer[183]. This
473 suggests that carcinomas might exploit polarity proteins to promote their progression.
474 For example, polarity proteins, when overexpressed, might switch from controlling
475 apical-basal cell polarity to regulate subcellular polarity (intracellular asymmetry),
476 which can improve cellular fitness to execute functions such as proliferation,
477 apoptosis, stress adaptation, stemness and organelle biology[163]. Membrane trafficking
478 processes are expected to be directly involved in the regulation of this polarity switch
479 and may thus contribute to the onset and progression of carcinomas.
480
481 **[H2] Tissue organization by mechanosensitive membrane trafficking.**
482 At variance with apical-basal cell polarity, planar cell polarity is a system of information
483 that provides cues along the axis parallel to the epithelial plane, and requires the
484 establishment of asymmetry within individual cells and the alignment of these
485 asymmetries across dozens or hundreds of cells. This is achieved through the proximal-
486 to-distal distribution, along the plane, of six planar cell polarity proteins
487 (Supplementary Box 1)[184-187]. The planar distribution of these proteins is driven by a
488 series of feedback loops, typically operative at the single cell level and dependent on
489 endocytosis and polarized membrane trafficking, as described in recent reviews[188,189].
490 Here, we will focus on additional, more recently described, endocytic mechanisms that
491 respond to tissue mechanics and control individual cell shape in the context of
492 supracellular, tissue-level organization.
493 One such mechanism involves the control of cell geometry and of the actomyosin
494 force-generation machinery, which regulate tissue rearrangements and size, as
495 elucidated in several developmental systems[190], including germband extension in *D.*
496 *melanogaster*[191,192]. Here, tissues undergo elongation to attain their final shape
497 through a process of cell intercalation that drives the so-called convergent extension
498 — a cell rearrangement whereby cells intercalate in an oriented fashion causing tissues
499 to shrink along the dorso-ventral axis and to elongate along the antero-posterior axis
500 (Figure 5a). At the level of neighbouring cells, dorso-ventral intercalation is the result
501 of the contraction of the interface between two dorso-ventral neighbours, followed by
502 the extension of the interface between the antero-posterior neighbours[193]. This occurs
503 through the combination of a tension-producing actomyosin network and adherens
504 junctions, which are governed by spatially restricted membrane trafficking, specifically
505 occurring along the surface of neighbouring cells[194]. Indeed, during germband
506 extension in *D. melanogaster*, clathrin and AP2 become enriched at the contractile
507 interface of neighbouring cells in the antero-posterior direction[195]; here, polarized
508 actomyosin contractility drives clustering and internalization of E-Cadherin, which
509 leads to junctional shrinkage by reducing local cell–cell adhesion[195].
510 The interplay between actomyosin contractility and endocytosis goes beyond
511 regulation of planar cell polarity, impinging also on the homeostatic control of tension
512 state and cell size in tissues, as occurs during the contraction of amnioserosa during
513 dorsal closure in *D. melanogaster*[196], and in adherens junction remodelling during
514 morphogenetic cell shape changes in mammalian epithelial tissues[197]. In the former
515 example (Figure 5b), adherens junctions tune their length and maintain junctional
516 straightness and tension while the whole tissue undergoes a global contraction[198].

517 When the tissue contracts, junctions shorten resulting in excess plasma membrane
518 that folds inwards, causing a reduction in membrane tension. Junctional and
519 membrane tension is restored by promoting removal of excess or folded plasma
520 membrane at junctions, through endocytosis[198]. The opposite occurs when junctions
521 are stretched, which results in the redistribution of actomyosin to adherens junction
522 for reinforcement, which increases tension that is then restored through inhibition of
523 endocytosis. Similarly, in various mammalian epithelial monolayers, endocytic
524 pathways act as mechanosensitive networks to stabilize junctional tension and length.
525 In these systems, junctions are dynamically remodelled by short pulses of RHOA-
526 mediated actomyosin contractility[197]. For pulses of RHOA activation that induce a
527 contraction capable of overcoming a defined strain threshold (*i.e.*, the maximal
528 deformation that epithelial cells within an epithelial tissue can undergo without
529 rupturing) associated with morphogenetic tissue shaping, junctions are permanently
530 relaxed and subsequently shortened in a process that requires endocytosis[197].
531 These findings highlight that changes in cell and tissue size are frequently driven by
532 pulsatile processes, where a directed dynamic process (*e.g.*, shortening of a junction)
533 alternates with periods in which force-generating networks are restored. This cycling
534 requires consolidation or "ratcheting" to lead to permanent changes, by preventing
535 the reversal of cell shape once the contractile network has dissipated. Membrane
536 trafficking operates as such a ratchet to ensure the removal of slackened membrane,
537 as mediated by RAB35 in germband extension[199,200]. At the antero-posterior interface,
538 RAB35 accumulates in compartments that dynamically grow and shrink on the minute
539 timescale. Genetic removal of RAB35 does not prevent the contractile cycles of
540 junctional length but impedes the permanent shortening of the cell interface (Figure
541 5b).
542 It is noteworthy that trafficking regulators, such as RAB35, appear to play multiple
543 roles in controlling the proper abscission of dividing cells[201] and integrin trafficking
544 during glandular morphogenesis[166], in addition to their role in tissue adaptation to
545 mechanical stresses. Indeed, the ability of tissues to adapt and respond to mechanical
546 perturbations has emerged as a key mechanism to ensure proper organ and
547 organismal development; whereas, failure to mount this mechanoresponse can lead to
548 patterning and structural abnormalities in the developing embryo. RAB35 also controls
549 the ability of cells to internalize nutrients through macropinocytosis[202] and was
550 identified as a pro-oncogenic mutated RAB capable of interacting with the regulatory
551 subunit of PI3K (p85) — a key oncogene — enhancing the activity of this kinase[203].
552 How this pro-oncogenic function of RAB35 impinges on glandular morphogenesis and
553 tissue mechanoadaptation is unknown, but it is tempting to speculate that RAB35
554 might be at the centre of a trafficking network that coordinates tissue shape, division
555 and growth, thus directly influencing tumorigenesis when its activity is perturbed[204].
556
557 **[H1] Endocytosis in collective cell migration**
558
559 One of the best characterized functions of endocytosis, beyond simply uptake of
560 extracellular cargo, is in the regulation of cell migration in physiology and in invasive
561 cell migration in cancer, as discussed in recent reviews[18, 205-207]. In this section, we will
562 focus on the regulation of cell migration by endocytosis, in the context of collective
563 modalities of migration with emphasis to their subversion in cancer (see also

564 Supplementary Table 2). In particular, we will discuss three emerging aspects of
565 endocytic regulation of collective migration: promoting persistent migration of cell
566 monolayers, modulation of tissue mechanical and material-like properties and
567 induction of EMT.
568
569 **[H2] Endomembrane dynamics controls collective motion.**
570 A function of endocytosis is the coordination of soluble and mechanical cues during
571 individual cell migration[7,10,208-210]. Frequently, however, cells are embedded in
572 multicellular ensembles, where the motion of the whole cell collective is overarching
573 with respect to individual cell locomotion. This occurs during the development of
574 epithelial layers (skin, digestive or respiratory tracts), in glandular organs, or during
575 wound healing. Collective motion may also take the form of cell clusters that maintain
576 cohesive interactions while migrating, as in the case of border cell migration in *D.*
577 *melanogaster*[211] or during the dissemination of epithelial cancers[212,213]. In these
578 situations, individual cells must coordinate their movement with that of their
579 neighbours, while keeping tight cell–cell interactions.
580 Multicellular migration is ruled by the biochemical and physical interactions that
581 cells establish with one another and their environment[214]. Indeed, physical forces
582 exerted by individual cells on their substrate or propagated, long-range, in
583 multicellular cohorts through cell–cell adhesions (via cadherins at adherens junctions),
584 are principal determinants of multicellular dynamics[215]. Establishing and maintaining
585 adherens junction strength, dynamics and polarity during cell migration is achieved by
586 trafficking membrane cadherins. One example here is collective migration of
587 astrocytes — major glial cells of the central nervous system — during development
588 and wounding[216]. Astrocytes migrate collectively through maintenance of connections
589 via N-Cadherin (aka CDH2). Developmental or wounding cues induce polarization of
590 astrocyte monolayer with the establishment of "leader cells" that determine the
591 migratory front. These leader cells extend lamellipodia, where actin treadmilling and
592 actomyosin contractility generate a retrograde flow of actin. N-Cadherin travels
593 backwards along this flow (retrograde transport along the plasma membrane). At the
594 back, N-Cadherin is endocytosed and through polarized trafficking delivered to the
595 front, to form new junctions[216], virtually installing a membrane trafficking treadmilling
596 process for N-Cadherin (Figure 6a), which can support persistent and cohesive
597 migration of the entire cell sheet.
598 Another example is the collective motion of the neural crest in *Xenopus laevis*[217],
599 where cells become fully migratory before they complete cell–cell dissociation,
600 thereby moving as collective clusters. A signalling mechanism, affecting junctional
601 adhesion strength, is triggered by lysophosphatidic acid (LPA)[218]. In the neural crest,
602 the interaction of LPA with its receptor, LPAR, specifically affects collective motion by
603 modulating the extent of cell–cell cohesion through internalization of N-Cadherin[219].
604 Neural crest collectives undergo a transition from a solid-like state, where local cell
605 rearrangements (the motion of a cell with respect to its neighbours) are not permitted,
606 to a fluid-like state, where reduced Cadherin adhesion allows local cell
607 rearrangement[219]. This results in fluidization of neural crest clusters, which can more
608 easily migrate into confined spaces, while retaining cell–cell cohesion.
609 LPA is a signalling lipid, abundant in blood, skin and ascitic fluids, which acts both as
610 mitogen and chemotactic agent. Melanoma and pancreatic cancer cells can

breakdown LPA, generating outward-facing local gradients — low in the tumour and high in the surrounding environment — that guide metastatic cell dispersal through a self-generated LPA chemotactic gradient[220,221]. Engagement of the LPAR stimulates its endocytosis in early endosomes. N-WASP, a promoter of branched actin polymerization, together with the endocytic protein SNX18, coordinate recycling of internalized LPAR from RAB11–RAB8-double positive endocytic tubules back to the plasma membrane preventing its degradation. The N-WASP-mediated LPAR recycling then ensures constant replenishment of the receptor at the plasma membrane allowing persistent RHOA activation, resulting in increased cell contractility, generation of traction forces and matrix remodelling for efficient cell migration. Loss of N-WASP affects invasiveness of pancreatic cancer cells pointing to N-WASP-dependent chemotaxis to LPA gradients as a motivator of egress from primary tumours and tropism towards metastatic sites[221]. In HeLa cells, the hyperactivation of the LPAR might also occur through trapping the receptor at the plasma membrane in coated plaques[222] (Box 1): reduced LPAR internalization prolongs its downstream signalling, representing an alternative mechanism to recycling for regulating actomyosin-based contractility. Whether coated plaques are operative in pancreatic cancer cells remains an issue for future investigations; notably, these structures are increased in cells plated on stiff substrates[33], suggesting that the hyper-stiff, stromal-rich, microenvironment of pancreatic cancer cells might favour their formation.

These findings highlight how an integrated biochemical and physical perspective is necessary for a holistic comprehension of the dynamics of multicellular entities and tissues. Such dynamics can be better understood by considering cell collectives as ensembles of “active particulate matter” that are, nevertheless, governed by structural and dynamic physical properties typical of amorphous viscoelastic materials[223,224]. During tissue growth, cells are free to move, as in a fluid, but their motion becomes constrained as cell density increases. At a critical cell density, motility ceases and collectives rigidify undergoing a liquid-like to solid-like transition referred to as tissue jamming[225-229]. This transition is thought to promote the development of elasticity and of barrier properties, but also to act as a suppressive mechanism for the growth of oncogenic clones.

Recently, it was shown that global perturbations of endocytosis — achieved by modulating the master regulator of early endosome biogenesis, RAB5A — impinges on biomechanical properties of cellular collectives. Increased RAB5A levels were sufficient to re-awaken the motility of “jammed” epithelial monolayers by triggering millimetre-scale, coherent and ballistic locomotion of multicellular streams that flow like “flocking” fluids[230], through the modulation of EGFR signalling (Figure 6b and 6c). In mammary epithelial cells, RAB5A induced EGFR-NCE, leading to accumulation of activated receptors in endosomes, whose size and number were remarkably elevated[231], and to elevation of endosomal ERK1/2 signalling, in keeping with the concept that endosomes act as quanta-like platforms where phosphorylated EGFR can be packaged at constant mean amounts[139]. In turn, this caused the hyper-phosphorylation of the Arp2/3 nucleating promoting factor, WAVE2, fuelling the extension of lamellipodia and directed cell motility[231] (Figure 6b).

Tumour cells can exploit this endocytic-mediated regulation of cell mechanics to facilitate their collective dissemination. Consistently, mammary tumour spheroids overexpressing RAB5 display persistent angular rotation and elevated local cell

rearrangements[231]. This leads to the generation of large traction forces on the surrounding extracellular matrix, resulting in its remodelling and the generation of tracks and channels into which tumour cells invade collectively. In another study, lowering of cell–cell adhesion with concomitant increase in 3D matrix confinement have been shown to affect unjamming transition and to foster collective invasion in breast cancer models[232]. These dynamics are reminiscent of those during body axis elongation in the zebrafish embryo, where a gradual solid-like to fluid-like transition is critical for promoting the elongation of the entire body axis[233]. Within this context, membrane trafficking might be a general mechanism to control the transition from a solid-like/jammed to a liquid-like/unjammed state, leading to progressive fluidization and collective motion.

[H2] Endocytosis and EMT

In addition to solid-to-liquid transition, another process contributing to collective motion of tissues is EMT. Unlike solid–liquid transitions, however, which rely on mechanical remodelling, EMT primarily involves changes of individual cell identity and state. Accordingly, recent evidence established that unjamming and EMT are very distinct processes differing not only in molecular machinery, but also in physical, dynamic, geometrical and structural properties[234]. Indeed, unjamming and EMT might be viewed as complementary gateways to cell migration, driving the escape of epithelial cells from a static, rigid and sessile state.

EMT is a process in which cells shift from a sessile epithelial to a migratory/invasive mesenchymal-like state[235]. Physiologically, it is involved in morphogenetic events, including gastrulation and neural crest migration[236]. Pathologically, EMT is exploited by cancer cells to acquire invasive/metastatic ability[237-239] — a process also connected with the acquisition of a cancer stem cell-like phenotype and drug resistance[240-243].

Various mechanisms act as initiators of EMT in cancer, including: growth factors and cytokines, components of the extracellular matrix and mechanical cues. Given the involvement of endocytosis in cell response to all these factors, it is not surprising that it controls EMT, at multiple steps in the process [244,245]. The common distal effectors, on which all these signalling pathways converge, are a set of transcription factors, which include Snail, Slug and ZEB1/2[246-248]. These transcription factors orchestrate the transcriptional repression of epithelial-specific genes that are critical in cell adhesion (*e.g.*, E-Cadherin), and the transcriptional activation of mesenchymal genes that reshape the cytoskeleton and the plasma membrane to permit migration (*e.g.*, N-Cadherin and vimentin). Thus, the actual enactment of the EMT program is generally viewed as a transcriptionally-driven process. This view is changing.

The key to understanding this renewed vision is the finding that, at least in some cases, EMT is not a binary process involving cell state conversion, but rather involves a plastic state in which cells can exhibit intermediate phenotypes, retaining some epithelial characteristics while acquiring some mesenchymal ones[236,237]. This state, called partial or plastic EMT (P-EMT), appears to be advantageous for cancer cells to oscillate between a mesenchymal phenotype, necessary to migrate out of the primary tumor, and an epithelial identity, necessary for survival and proliferation once they reach the final metastatic niche[249]. Cell context is emerging as a determining factor for the decision to adopt a full EMT *vs*. a P-EMT state: in this latter instance, endocytic mechanisms appear paramount over transcriptional ones. Cancer cells adopting the

“endocytic” modality to achieve P-EMT, lose their epithelial phenotype through surface protein internalization rather than through the action of EMT-promoting transcription factors[250]. In particular, E-Cadherin is actively internalized and sequestered in RAB11-positive recycling endosomes, consistent with the notion that the molecular alteration behind the cell state shift resides in a blockade of the physiological recycling of E-Cadherin to the plasma membrane.

In this contention, we note that the “endocytic mechanism” of P-EMT has the characteristics of being more rapidly reversible (through re-induction of recycling) and perhaps less extensive than the transcriptional reprogramming, thus being more adapt to the plastic state of P-EMT. It is also interesting that cells adopting the endocytic-based P-EMT modality, exhibit a collective, rather than individual, mode of migration, characteristic of cells displaying full EMT[250]. Furthermore, it has been shown that cancer cells adopting different degrees of EMT, tend to metastasize to different sites[251] raising the interesting question of whether a primary alteration of endocytic mechanisms, in some tumours, might underlie metastatic organotropism.

[H1] Conclusions and perspectives

Since the first hints, more than a quarter of century ago, that endocytosis could sustain and/or diversify cell signalling[252-254], rather than merely extinguishing it, a wealth of literature has accumulated, which not only supports this concept but extends it to virtually every area of cell regulation[1,255]. The field is now mature to address the next question: that of the significance of cellular context of endocytic regulation.

In this vision, the same signalling circuitry could elicit substantially different biological outputs based on the “endocytic landscape” in which it is embedded and regulated by. Although the concept of the existence of specific endocytic landscapes in cells, herein proposed, is at present molecularly vague, we would like to draw one example that may support it. The EGFR is internalized by two types of CME, by FEME and by EGFR-NCE, which all impact differently on receptor fate, signalling properties, and timing of signals (see section Endocytic regulation in context). They also display cell context specificity. Thus, cell-specific “endocytic landscapes” are projected to differentially affect the EGFR signalling output — an issue of great pathophysiological relevance, given the importance of this RTK to cancer[88,89].

There are clever approaches being pursued to investigate this hypothesis. One is that of exploiting isogenic models of cells differentiated in vitro from multipotent cells (embryonic stem cells or induced pluripotent cells). Using this approach, it was shown that isogenic, diversely differentiated cells display remarkable variations in the dynamics and structure of clathrin coats[40]. These differences hinged on context-dependent variations in AP2 levels and in the requirement for PI3K activity[40]. Another approach is to employ organoids that recapitulate the complex differentiation patterns that occur in vivo[256]. This approach, coupled to advanced imaging to detect live endocytic dynamics and to single-cell sequencing, to decipher the endocytic landscape of individual cells, should substantially improve our understanding of cell context in individual and collective cellular behaviour.

The same view could be extended to the domain of endocytic alterations in cancer. In this case, perhaps, the simple idea of endocytic proteins acting as oncogenes or tumour suppressors, albeit valid in some cases[1,17,18], might be too narrow. The

evidence that the endocytic context might skew the output of a signalling pathway towards different biological outcomes, opens up the possibility that differences in the expression of groups of endocytic proteins (the "endocytic landscape") might render cells more or less prone to respond to oncogenic insults and, therefore affect the propensity of cells for tumorigenic transformation. In this contention, we note that genetic alterations of endocytic proteins are infrequent in cancer[1,17,18]; rather, the more common alteration is their over- or under-expression, which often correlates with metastasis and disease outcome[6,18] (see also Supplementary Tables 2 and 3) To extend our knowledge, we should go beyond the "one protein at the time" approach and embrace comprehensive profiling of tumours, to identify endocytic landscapes that might define the propensity of certain tumors (or subgroups of tumours) to adopt different individual or collective cell behaviours (even in response to the same signalling input), especially those relevant to the invasive/metastatic phenotype.

Acknowledgments

We thank Maria Grazia Malabarba for support in figure design and Rosalind Gunby for critically editing the manuscript before submission. Work in the authors' labs is supported by: Associazione Italiana per la Ricerca sul Cancro (AIRC IG 24415 to SS, AIRC IG 22811 to LL, AIRC IG 18621 and 5XMille 22759 to GS, and AIRC IG 18988, AIRC IG 23060 and MCO 10000 to PPDF); the Worldwide Cancer Research (20-0094 to SS), the Italian Ministry of University and Scientific Research (PRIN 2017, Prot. 2017E5L5P3 to SS; Prot. 2017HWTP2K to GS; PRIN 2015 Prot. 2015XS92CC to PPDF); the University of Milan (PSR2019 to SS); the FPRC 5x1000 Ministero Salute 2017 (to LL); the Italian Ministry of Health (RF-2016-02361540 to PPDF).
We apologize to the many colleagues whose excellent work could not be reviewed or cited for lack of space. An additional number of primary research papers and reviews is included in Supplementary Information.

Competing interests

The authors declare no competing interests.

Figure Legends

Figure 1. Heterogeneity of clathrin-coated pits.
Clathrin-mediated endocytosis (CME) is a heterogeneous process, with a variety of clathrin-coated pits (CCPs) that differ in their composition, leading to different fates of the endocytic cargo. **a**. In physiological conditions, transferrin (Tf) receptor (TfR) internalization depends on clathrin adaptor AP2 only[48-51]. After endocytosis, the iron bound to Tf is released in an endosomal compartment and the Tf–TfR complex is recycled back to the surface[257]. **b**. Low-density lipoprotein (LDL) receptor (LDLR) endocytosis relies on the cargo-specific adaptors, DAB2 and ARH, in addition to AP2 (refs. [258-263]). In the endosomal compartment, the LDL moiety is released and committed to lysosomal degradation (and the LDL-bound cholesterol is released),

while the “empty” receptor is recycled to the cell surface[264]. **c**. Agonist-activated G protein-coupled receptors (GPCRs) bind heterotrimeric G-proteins (α, β, γ) which triggers “canonical” G-protein-mediated signalling at the plasma membrane[111]. Receptor desensitization occurs by phosphorylation (P) of the active receptor by GPCR kinases (GRKs) and subsequent binding of β-arrestin, resulting in dissociation of the G-protein complex and of its interaction with the receptor. Further desensitization occurs when the β-arrestin bound GPCR is sequestered into distinct CCPs and internalized, to be either recycled back to the plasma membrane or degraded in the lysosome (not shown)[41]. Receptor ubiquitylation (Ub) and PDZ-containing scaffold proteins, linking the GPCR to the actin cytoskeleton, determine increased surface retention of GPCR-containing CCPs and their slower kinetics, promoting cargo clustering and β-arrestin-dependent “non-canonical” signalling[41-44]. **d**. Epidermal growth factor receptor (EGFR) can be internalized through different CCPs[51]: AP2-dependent CCPs mostly commit the receptor to recycling, sustaining signalling; AP2-independent CCPs, which rely on the EPS15 and/or EPS15L1 and EPN1 adaptors, target the EGFR to lysosomal degradation[51]. **e**. Dynamin2 (DYN2) is ubiquitously and constitutively involved in CCP maturation and fission (parts a-d)[62-66]. By contrast, dynamin1 (DYN1) is employed in clathrin-mediated endocytosis only under specific conditions; *e.g.*, in EGF stimulated non-small cell lung cancer cells where the inhibitory constraints of GSK3β-dependent DYN1 phosphorylation are removed[36,65,68]. In cancer, the GSK3β kinase can be inactivated (not shown) or targeted for degradation due to aberrant activation of AKT kinase, leading to DYN1 dephosphorylation and aberrant activation, and eventually to deregulated EGFR endocytosis, signalling and migration[66,73].

Figure 2. NCE mechanisms and cellular contexts.

a. CLIC/GEEC (clathrin-independent carrier/GPI-anchored protein-enriched early endosomal compartment) requires extracellular clustering of glycosylated cargoes (through galectins) to induce membrane bending, and small GTPases (ARF1, CDC42) that coordinate the activation of actin nucleators (Arp2/3) and regulators (NWASP)[2,15]. Bar-domain proteins (GRAF1, IRSP53, PICK1) control the initial phase of vesicle formation, while endophilinA2 (EndoA2) is required for fission, together with the pulling force of the actin cytoskeleton and the microtubule-associated motor protein, dynein: a mechanism known as “friction-mediated scission”[265,266]. The internalized vesicle fuses with an endosomal GEEC compartment from which cargoes are recycled[2,15]. **b**. Fast endophilin-mediated endocytosis (FEME), which is active in the same cells as CLIC/GEEC[85], also requires the action of actin, actin nucleators, and BAR-domain proteins. EndoA2 is required for vesicle formation and fission (together with dynein, microtubules and DYN2)[85]. FEME internalizes epidermal growth factor receptor (EGFR) stimulated with high EGF, and other cargoes, including other receptor tyrosine kinases (RTKs) and G protein-coupled receptors (GPCRs)[84]. **c**. High EGF also induces EGFR-NCE, which requires EGFR ubiquitylation (Ub) and Ub receptors (EPS15, EPS15L1 and EPN1)[56], plasma membrane–ER contacts mediated by the ER transmembrane protein RTN3, and Ca^{2+} release at plasma membrane–ER contacts (of note, some mechanistic aspects of EGFR-NCE are still missing, *e.g.*: Which are the factors involved in plasma membrane–ER tethering? Is RTN3 directly recruited to the EGFR? Which is the exact role of EGFR ubiquitylation and Ub receptors?)[87]. EGFR-dependent signalling occurs at the plasma membrane and in endosomes through ERK1/2 (refs. [139,231]).

846 Notably, activated ERK1/2 and EGFR might not accumulate on the same endosome
847 after CME[267]. They might, instead, do so in cells expressing high EGFR and treated with
848 high EGF concentrations, or expressing elevated RAB5A (ref. [231]) (see also Fig. 6),
849 where EGFR-NCE and massive activation of pinocytotic processes occur[268]. Eventually,
850 EGFR-NCE targets the EGFR to lysosomal degradation, restricting signalling in a cell
851 context-dependent fashion[86,269]. **d**. The interleukin-2 (IL-2) receptor (IL-2R) complex
852 (comprising α, β, subunits) is expressed in lymphocytes and signals through JAK–
853 STAT[270]. IL-2R is internalized via an NCE mechanism occurring in proximity of actin-
854 enriched membrane protrusions that facilitate actin polymerization and plasma
855 membrane invagination[90,271-273]. Once internalized, the α chain is recycled, whereas
856 the β and γ chains are degraded[91]. **e**. Macropinocytosis internalizes pathogens,
857 apoptotic cells/debris and proteins through the formation of actin-dependent plasma
858 membrane protrusions[101]. Internalized materials are delivered to the lysosome. In the
859 lysosome, pathogen-derived antigens are generated and bind to MHC receptors (in
860 immune cells), which are targeted to the plasma membrane for antigen
861 presentation[102]. Apoptotic cells/debris and proteins are degraded in lysosomes and
862 used by epithelial cells (particularly, cancer cells) for nutrient scavenging[103,107-109].
863
864 **Figure 3. Membrane trafficking in apical-basal cell polarity.**
865 The apical-basal polarity complexes (see Supplementary Box 1) are shown as green
866 ovals, including their main protein components. Epithelial polarity is maintained
867 through coordinated and polarized trafficking of the various components of these
868 complexes, achieved through distinct endosomal intermediates, regulated by different
869 RAB GTPases, as shown[274]. There is bidirectional connection between polarity
870 complexes and membrane traffic. For instance, RAB11-dependent apical transport
871 pathways reinforce the localization of the apical PAR complex, while apical PAR3,
872 controls the subapical positioning of RAB11-positive endosomes[171,275].
873 A number of other apical and basolateral cargoes enter spatially distinct,
874 peripherally localized apical or basolateral early endosomes (AEE or BEE), respectively,
875 and undergo alternative fates[276]. They can be either recycled to the plasma membrane
876 (not shown), or routed to RAB8—RAB10-double positive common recycling
877 endosomes (CRE)[277,278]. CREs are so named because they are the target of both apical
878 and basal cargoes, which are then either shuttled to the basolateral surface, or
879 delivered to the apical recycling endosomal (ARE) compartments, before being
880 directed to the apical surface[276]. For example, basolateral proteins – such as E-
881 Cadherin or transferrin receptor – are targeted from CRE to the basolateral plasma
882 membrane via a pathway that involves the AP1B coat protein as well as the exocyst
883 protein complex (not shown)[279]. An example of an apical cargo that traffics via AREs to
884 the apical plasma membrane is H^+/K^+-ATPase of gastric parietal cells[280].
885 Neosynthesized proteins can also be delivered, via Golgi, to their destinations (apical
886 or basolateral) either directly (not shown) or indirectly through AREs or CREs. The
887 green arrow points to the aPKC/LGL circuitry described in Supplementary Box 1.
888
889 **Figure 4. Membrane trafficking in apical lumen formation**.
890 Lumen formation in epithelial monolayers requires coordination between cell division,
891 actin polymerization and membrane trafficking[160,171,281] (events are shown across two
892 cells for clarity but they occur in both cells). **a**. Following cell division, at the midbody,

the apical membrane initiation site (dashed box) is established, through the coordination and re-organization of microtubules (not shown) and branched actin filaments, via RAC1—WAVE to promote recruitment of cingulin. A positive feedback loop (asterisk) involving branched actin polymerization, ZO1 and cingulin further sustains the establishment of the apical membrane initiation site (whereby cingulin promotes branched actin polymerization, which supports recruitment of ZO1 and consequently recruitment of cingulin via its interaction with ZO1)[172]. At this stage, early polarity determinants such as podocalyxin or IRSP53, are present on the plasma membrane facing the outer surface. **b**. Multiple endocytic and transport events (1) direct apical determinants (podocalyxin and IRSP53 are shown, but there are several others) to the apical membrane initiation site, where the exocytosis of membrane and apical proteins results in formation of a nascent lumen (2). IRSP53 senses and stabilizes the negative curvature of the membrane via its I-BAR domain, which ensures the integrity and shape of the opposing membranes of the two neighbouring cells for correct lumen generation. RAB11–RAB8-double positive endosomes are critical in this phase (3 and inset)[171], as they become restricted towards the luminal side, ideally positioned to dock and fuse at the apical membrane through multiple interactions. These endosomes can be tethered to the apical membrane initiation site by binding to cingulin (via FIP5–RAB11 (4)], by binding to RAB35 directly (5) or through tethering with the exocyst complex (including MYO5B, Sec15a and SEC10)[282] (6, inset). Among the cargoes transported by the RAB8–RAB11 vesicles, are annexin2 and CDC42, which are directed apically to interact with apical polarity complex component aPKC (7, inset; see also Supplementary Box 1 for details on epithelial polarity)[171]. Thus, a self-sustained polarized transport system of apical determinants is essential and precedes the formation of a tight junction-delimited lumen. **c**. Subsequent cell divisions expand the luminal space and increase the size of the luminal cyst through a combination of water influx through solute carriers that increases hydrostatic luminal pressure (blue arrows) and reduced actomyosin contractility (red arrows; the exact molecular mechanisms are unclear) along the forming tight and adherens junctions.

Figure 5. Endocytosis and actomyosin in the control of cell shape and tissue elongation.

A. Diagrammatic representation of cell intercalation in *Drosophila melanogaster* germband extension[193] (the arrows show the developmental axes: A, anterior; P, posterior; D, dorsal; V, ventral.). T1, T2, T3 indicate the different phases of the process. During the T1-to-T2 transition, the antero-posterior interface between two adjacent cells shrinks to a four-cell vertex (T2, which defines a state where the sides of four adjacent cells converged into a single focal point indicated with a red dot). This is thought to occur because of increased actomyosin medial contraction that generates forces directed along the antero-posterior plane (1). This event is accompanied by elevated and localized clathrin-mediated endocytosis (CME) of junctional molecules, such as E-Cadherin[193,195] (2). In the T2-to-T3 transition, the four-cell vertex expands to generate a new cell-junctional surface oriented along the dorso-ventral interface that leads to effective tissue elongation along the dorso-ventral axis. **b**. Contraction of amnioserosa in dorsal closure in *D. melanogaster*[196], and in morphogenetic junction remodelling in mammalian epithelial tissues[197]. In the initial step, changes in RHOA-mediated activity result in increased medial-apical actomyosin contractility (1) that

940 causes cell areas to oscillate leading to increased junctional tension (2). During area
941 oscillations, RAB35 endocytic activity is enhanced resulting in increased endocytosis
942 (3). This aims at reduction of plasma membrane tension. Concomitantly,
943 internalization of the plasma membrane and various plasma membrane cargo proteins
944 (*e.g.*, E-Cadherin) leads to shortening of the junctional interfaces[196] (4). Myosin II and
945 CME are required to terminate the RAB35 intermediate compartment (not shown) and
946 to direct endocytosed materials to endosomes. This process of internalization of the
947 plasma membrane and junctional molecules functions as an effective ratcheting device
948 to remove excess membrane and to maintain the reduced length of cell–cell junctions.
949 However, through not yet fully understood mechanisms, cargoes – such as CDH1 – can
950 be routed back from endosomes to the interface between the two cells (5), thereby
951 replenishing the membrane and interfacial components and ensuring the reversibility
952 of the interface contraction (6).
953
954 **Figure 6: Endomembranes in the dynamics of collective motion.**
955 **a**. The treadmilling cycle of N-Cadherin in developmental collective motion of
956 astrocytes. Cells at the front show protrusive edges. F-actin attachment to adherens
957 junction components (catenins and N-Cadherin) drives their retrograde flow (1) along
958 lateral contacts (2). At the rear, phosphorylation (P) of p120-catenin by GSK3 untangles
959 the complex (3) allowing for N-Cadherin endocytosis (4) and polarized recycling to the
960 leading edge where GSK3 is inactive (5)[216]. **b**. In epithelial 2D and 3D collectives that
961 depend on epidermal growth factor receptor (EGFR) activation for proliferation and
962 motility, the elevation of RAB5A triggers non-clathrin endocytosis (NCE) of the
963 activated EGFR leading to the concomitant expansion in the size and number of
964 endosomes. This results in sustained ERK1/2 signalling from endosomes. ERK1/2
965 signalling promotes the phosphorylation of WAVE2 (WAVE2-P)[231], which, in the
966 presence of activated RAC1, leads to the activation of Arp2/3 complex and branched
967 actin nucleation[283,284] leading to the formation of "cryptic lamellipodia"[285]. These
968 structures extend beneath neighbouring cells and drive persistent, coordinated cell
969 motion and efficient cell re-orientation, which, together with elevated junctional
970 tension (not shown), results in unjamming of the entire monolayer[138,231,286,287]. **c.**
971 Snapshots representative of two distinct states of densely packed epithelial collectives
972 in the presence or absence of RAB5A expression[138]. The velocity vectors (black arrows)
973 of each individual centroid are shown. Jammed immobile, control monolayers display
974 randomly oriented poorly motile cells. RAB5A expression increases cell velocity and
975 promotes the alignment of the velocity vectors. This results in monolayers displaying a
976 flocking mode of motion where long-range collective motion and short-range, local cell
977 arrangements are permitted (not shown). The colour code indicates regions within the
978 monolayer with velocity vectors that are either parallel (yellow) or antiparallel (blue)
979 to the mean direction of migration.
980
981 **Box 1. Clathrin-coated plaques: role in mechanosensing, adhesion and mitosis.**
982 Clathrin-coated plaques (CPLs) are long-lived plasma membrane structures enriched in
983 integrins and various signalling receptors but not actin[32,33], that are regulated by the
984 physical properties of the extracellular matrix (ECM). As the substrate rigidity
985 increases, CPLs assemble and expand. By linking CPLs to the substrate, integrin $\alpha v\beta 5$
986 delays their budding, in a process called "frustrated endocytosis", ultimately stabilizing

them[33]. Thus, CPLs might represent mechanosensitive adhesion platforms, generated as a consequence of “frustrated endocytosis”[33] (see figure). CPLs are present in interphase cells (left in figure), together with “canonical” focal adhesion complexes, which are enriched in integrins, focal adhesion kinase (FAK), actin, vinculin, talin and paxillin. At mitosis (right in figure), the actin cytoskeleton is reorganized to form a contractile cortical network of actin filaments, which promotes a cellular morphological change, known as “rounding up”. During cell rounding for mitosis, a decrease in cell surface area is achieved and endocytosis continues, albeit at a lower rate, while recycling is impaired[288-290]. At the same time, “canonical” focal adhesion complexes are disassembled, while “mitotic” adhesion complexes are established to preserve the interaction with the substrate needed to achieve daughter cell re-spreading and mitotic spindle orientation[291-294]. These mitotic adhesion complexes and CPLs are likely the same type of structure[34] since they share several properties. Both types of structures are very stable with slow plasma membrane turnover; they are composed mainly of integrins, while actin is not enriched and does not play any role in their dynamics; they are enriched in endocytic proteins. In addition, their number and size increase with the increase of the rigidity of the substrate[293]. Another function of CPLs (not shown in the figure) is to act as adhesive structures in non-mitotic cells migrating in 3D environments. In this case, they are assembled on linear collagen fibres and provide multiple anchoring sites to the ECM along cell protrusions in order to support 3D cell migration, in cooperation with classical focal adhesions[295].

Glossary

Receptor tyrosine kinases

A family of plasma membrane proteins (~ 60 genes in humans) that function as high affinity binding sites for growth factors and cytokines and transduce signals intracellularly through their intrinsic tyrosine kinase activity.

G protein-coupled receptors

A vast family of plasma membrane receptors (more than 800 genes in humans) characterized by seven transmembrane regions. They transduce signals through a variety of modes, among which the best characterized one is the coupling with heterotrimeric G proteins.

Arrestins

A family of proteins that act as multifunctional scaffolding proteins, regulating trafficking and signaling of transmembrane receptors, particularly of GPCRs. They are involved in receptor desensitization, endocytosis and ubiquitylation. They can also function as positive effectors of GPCRs through their scaffolding abilities. The arrestin family comprises visual arrestins, β-arrestins (non-visual arrestins) and α-arrestins

Epsin family of endocytic adaptor proteins

A family of endocytic proteins composed of 3 paralogs: EPN1, EPN2 and EPN3, characterized by the presence of an epsin N-terminal homology (ENTH) domain involved in phosphoinositide binding at the plasma membrane, ubiquitin binding

1034 motifs (UIMs), as well as motifs that bind to clathrin, AP2 and other endocytic proteins.
1035 They are involved in both CME, where they play a role in clathrin-coat assembly and
1036 cargo recruitment, and in EGFR-NCE.
1037
1038 **Epithelial-mesenchymal transition (EMT)**
1039 This is a process, of great relevance in embryogenesis, through which epithelial cells
1040 lose polarity and cell–cell adhesion contacts (sessile state) to acquire characteristics of
1041 migratory mesenchymal-like cells. In physiology, typically, after migrating, these cells
1042 re-acquire an epithelial phenotype through the opposite process of mesenchymal--
1043 epithelial transition (MET).
1044
1045 **Death receptors**
1046 Death receptors are type I transmembrane proteins belonging to the tumor necrosis
1047 factor/nerve growth factor superfamily. They are activated upon binding to various
1048 agonists (such as FASLG, TNFA or TRAIL). They typically trigger the so-called apoptotic
1049 extrinsic pathway, yet they can also activate multiple alternative signaling pathways
1050 with opposing outcomes (survival/proliferation *vs.* cell death) depending on the cell
1051 context.
1052
1053 **Caveolae**
1054 Small flask-shaped invaginations of the plasma membrane (50–80 nm) that can be
1055 morphologically identified by the presence of coat-like proteins, caveolins, and that
1056 are particularly abundant in tissues involved in lipid homeostasis or subjected to
1057 mechanical challenges like adipocytes, muscle and endothelial cells.
1058
1059 **Vinculin**
1060 A protein involved in the formation of focal adhesions that links surface structures
1061 (integrins) to the actin cytoskeleton (through binding to F-actin).
1062
1063 **Focal adhesions**
1064 Cell-to-matrix adhesion structures involved in the transmission and regulation of
1065 signals between the extracellular matrix and the intracellular environment. They are
1066 large and dynamic protein complexes established through integrins (which bind to the
1067 extracellular matrix), vinculin, F-actin and several regulatory components (up to
1068 hundred different proteins, according to the state of the cell). Focal adhesions have
1069 roles in signal transduction, cell motility, cell cycle regulation and several other cellular
1070 phenotypes. They represent one of the main sensors/effectors in cellular
1071 mechanosensing.
1072
1073 **Tip cells**
1074 During angiogenesis, new vessels that sprout from existing ones are guided by a leader
1075 cell that drives the extension of the sprout and senses the environment for guidance
1076 cues.
1077
1078 **ERK signalling**
1079 Is the signalling mediated by the activation of the extracellular signal regulated kinases
1080 (ERKs, also called mitogen-activated protein kinases or MAPKs). This signalling is

1081 mediated by the sequential activation of the small GTPases RAS, and a cascade of
1082 kinases (RAF, MEK, and ERK1,2) that transduce a signal from a receptor, located on the
1083 cell surface or on endosomes, to regulate as number of fundamental biological
1084 function, including cell proliferation, differentiation and migration.
1085
1086 **PAK**
1087 A family of serine/threonine protein kinases that includes six members in mammals.
1088 They serve as targets for the small GTPases CDC42 and RAC and have been implicated
1089 in a wide range of biological activities.
1090
1091 **PTEN**
1092 A lipid phosphatase (phosphatidylinositol 3,4,5 triphosphate 3-phosphatase). It
1093 catalyses the conversion of PI(3,4,5)P3 to PI(4,5)P2, thereby antagonizing the action of
1094 PI3K and the activation of AKT. It represents one of the most frequently lost tumor
1095 suppressors in human cancers
1096
1097 **AMPK**
1098 AMP-activated protein kinase or 5' adenosine monophosphate-activated protein
1099 kinase. It is a heterotrimeric protein complex endowed with serine/threonine kinase
1100 activity which regulates the energy metabolism, mostly acting on glucose and fatty
1101 acid metabolism.
1102
1103 **RAC1**
1104 A member of RHO subfamily of small GTPases that plays a central role in controlling
1105 the activity of protein complexes that are necessary to remodel the actin cytoskeleton
1106 during migration.
1107
1108 **P38**
1109 A member of a class of mitogen-activated protein kinases (MAPKs) that are responsive
1110 to stress stimuli, such as cytokines, ultraviolet irradiation, heat shock, and osmotic
1111 shock, and are involved in cell differentiation, apoptosis and autophagy.
1112
1113 **JNK**
1114 JNK (or c-Jun N-terminal Kinase), is a member of a family of protein kinases, which play
1115 a central role in stress signalling pathways implicated in gene expression, neuronal
1116 plasticity, regeneration, cell death, and regulation of cellular senescence.
1117
1118 **RAB GTPases**
1119 A subfamily of small GTPases that includes more than 70 members in mammals and
1120 regulates several key steps of membrane trafficking, including vesicle formation,
1121 vesicle movement along actin and tubulin networks, and membrane fusion.
1122
1123 **GEF**
1124 This term defines broadly a vast group of proteins (frequently unrelated) which all
1125 possess Guanine Nucleotide Exchange Factor activity, *i.e.*, the ability to convert G
1126 proteins from an inactive GDP-bound to an active GTP-bound form.
1127

"Jammed" epithelial monolayers
The dynamics of epithelia has been described in terms of jamming transitions. During this transition, collective motion ceases, cells can no longer exchange neighbours, and monolayers become static and rigid, displaying a behaviour similar to that of ensembles of dense and packed inactive particles, such us coffee in a chute or sand in a pile.

WAVE
A key component of a pentameric actin nucleation promoting complex which acts downstream of the GTPase RAC, and is necessary for activating the ARP2/3 complex for the generation of branched actin networks.

Midbody
Central region of the thin cytoplasmic bridge that connects cells at the end of cytokinesis. It consists mostly of microtubules, together with various other types of proteins (400-500). It functions as a platform to mediate abscission, the process of severing the intercellular bridge. It is also endowed with numerous other functions, including determination of cell fate and asymmetric post-abscission signal transduction.

Tight junction
A cell-to-cell junction formed by a multiprotein complex. This type of junction is established through homotypic interactions between adhesion molecules (occludins, claudins, JAMs) present on the surface of abutting cells. Tight junctions mark the border between the apical and the basolateral surfaces in epithelial cells and control the formation of functionally distinct apical domains. They are also present in endothelial cells and astrocytes and establish the blood-brain barrier. One of their major function is to seal the epithelia by preventing leakage of water and small molecular weight solutes.

Arp2/3 complex
A seven-subunit complex that upon activation promotes the branched elongation of the actin network by binding to the side of mother filaments.

Crumbs polarity complex
A multiprotein complex composed of three members originally identified in *Drosophila*, Crumbs, Pals1 and PatJ. This complex plays a key role in specifying the apical plasma membrane domain of epithelial cells and in controlling cell shape in both invertebrates and vertebrates.

Transcytosis
A process in which molecules are transported across cellular barriers. It involves the endocytosis of molecules (typically plasma membrane proteins or extracellular molecules captured through interaction with surface receptors) at one side of the cell and their vesicle-mediated transport to another side, where they are released through exocytosis. It contributes to the establishment of apical-basal cell polarity by transferring transmembrane proteins between distinct plasma membrane domains. It

is involved in many other processes, for instance the crossing of the blood-brain barrier.

Exocyst

An octameric protein complex involved in vesicle trafficking, specifically in the tethering and spatial targeting of vesicles to the plasma membrane prior to vesicle fusion.

Annexin-2

A 36-kDa calcium-dependent, phospholipid-binding protein that functions in promoting the exocytosis of intracellular proteins to the extracellular space.

CDC42 apical polarity complex

CDC42 is a highly conserved RHO-family GTPase that regulates cell polarity in many eukaryotes. It directly interacts with PAR6, and regulates, through this protein, the activity of the atypical protein kinase C, aPKC.

BAR domain

This is a banana-shaped protein domain capable of sensing membrane curvature by binding preferentially to curved membranes. BAR domains are named after three proteins in which they were originally identified: BIN1, bridging interactor 1; AMPH, amphiphysin; and Rvs167, the yeast homolog of amphiphysin.

Adherens junctions

Cadherin-based cell-to-cell junctions present in epithelial and endothelial cells, frequently in a more basal position with respect to tight junctions.

Isochoric

A process in which the volume of a closed system does not change. It is synonym of isovolumetric.

Germband

In *Drosophila melanogaster*, the ventral part of the embryo that forms during gastrulation and gives rise to the segmented trunk of the animal (gnathal, thoracic, abdominal segments). It includes the mesoderm, ventral ectoderm and dorsal epidermis but excludes the dorsal-most tissue of the embryo, the amnioserosa.

Amnioserosa

In *Drosophila melanogaster*, a short-lived extraembryonic tissue with a critical role in dorsal closure and other early developmental morphogenetic events.

Border cells

A cluster of cells that migrate from the anterior tip of the Drosophila egg chamber to the border of the oocyte at stage 9 of Drosophila oogenesis. These cells perform a stereotypical collective migration on the intervening nurse cells, and reach the oocyte. They are required for the formation of the micropyle, the eggshell structure through which sperm enters the egg.

Lamellipodia
Thin membrane protrusion present at the leading edge of migrating cells, mostly constituted by a flat network of actin.

Treadmilling
A process characterizing filamentous multimeric protein structures within the cell and mostly used in reference to filamentous actin (F-actin). When actin subunits (G-actin) are constantly added at one end of the filament and removed from the opposite one, the net effect is the treadmilling of the filament which is used, for instance, to generate motion. The term is also used, more generally, for other biological processes in which "treadmilling" of molecules or organelles occurs.

Neural crest
A temporary group of cells established during vertebrate development, which forms after gastrulation at the border between the neural plate and the surrounding ectoderm. After closure of the neural tube (due to the folding of the neural plate into itself), the neural crest runs along the roof plate of the neural tube. At this stage, neural crest cells undergo epithelial-mesenchymal transition and migrate to the periphery, where they give origin to various cell lineages.

Ascitic fluid
An abnormal accumulation of fluid in the abdominal cavity frequently caused by liver disease or cirrhosis, cancers, specifically ovarian and colon cancer, and heart failure.

AKT kinase
The three members of the human AKT serine-threonine protein kinase family are often referred to as protein kinase B alpha, beta, and gamma. These proteins are phosphorylated by phosphoinositide 3-kinase (PI3K). AKT/PI3K forms a key component of many signalling pathways that involve the binding of membrane-bound ligands such as receptor tyrosine kinases.

Galectins
A class of proteins that bind specifically to β-galactoside sugars, such as N-acetyl-lactosamine. Galectins are secreted in the extracellular space, where they encounter galactose-containing glycoproteins and glycolipids. Binding of galectins to glycosylated proteins, such as CD44 and α5β1 integrin, triggers galectin oligomerisation, which allows their interaction with glycosphingolipids and the generation of plasma membrane curvature, leading to the formation of clathrin-independent endocytic carriers (CLICs).

References

1 Sigismund, S. *et al.* Endocytosis and signaling: cell logistics shape the eukaryotic cell plan. *Physiol Rev* **92**, 273-366, doi:10.1152/physrev.00005.2011 (2012).

1268 2 Thottacherry, J. J., Sathe, M., Prabhakara, C. & Mayor, S. Spoiled for Choice:
1269 Diverse Endocytic Pathways Function at the Cell Surface. *Annu Rev Cell Dev Biol*
1270 **35**, 55-84, doi:10.1146/annurev-cellbio-100617-062710 (2019).
1271 3 Goh, L. K. & Sorkin, A. Endocytosis of receptor tyrosine kinases. *Cold Spring Harb*
1272 *Perspect Biol* **5**, a017459, doi:10.1101/cshperspect.a017459 (2013).
1273 4 Irannejad, R., Tsvetanova, N. G., Lobingier, B. T. & von Zastrow, M. Effects of
1274 endocytosis on receptor-mediated signaling. *Curr Opin Cell Biol* **35**, 137-143,
1275 doi:10.1016/j.ceb.2015.05.005 (2015).
1276 5 Villasenor, R., Kalaidzidis, Y. & Zerial, M. Signal processing by the endosomal
1277 system. *Curr Opin Cell Biol* **39**, 53-60, doi:10.1016/j.ceb.2016.02.002 (2016).
1278 6 Lanzetti, L. & Di Fiore, P. P. Behind the Scenes: Endo/Exocytosis in the Acquisition
1279 of Metastatic Traits. *Cancer Res* **77**, 1813-1817, doi:10.1158/0008-5472.CAN-16-
1280 3403 (2017).
1281 7 Wilson, B. J., Allen, J. L. & Caswell, P. T. Vesicle trafficking pathways that direct
1282 cell migration in 3D matrices and in vivo. *Traffic* **19**, 899-909,
1283 doi:10.1111/tra.12605 (2018).
1284 8 Disanza, A., Frittoli, E., Palamidessi, A. & Scita, G. Endocytosis and spatial
1285 restriction of cell signaling. *Mol Oncol* **3**, 280-296,
1286 doi:10.1016/j.molonc.2009.05.008 (2009).
1287 9 Eaton, S. & Martin-Belmonte, F. Cargo sorting in the endocytic pathway: a key
1288 regulator of cell polarity and tissue dynamics. *Cold Spring Harb Perspect Biol* **6**,
1289 a016899, doi:10.1101/cshperspect.a016899 (2014).
1290 10 Sigismund, S. & Scita, G. The 'endocytic matrix reloaded' and its impact on the
1291 plasticity of migratory strategies. *Curr Opin Cell Biol* **54**, 9-17,
1292 doi:10.1016/j.ceb.2018.02.006 (2018).
1293 11 Katsuno-Kambe, H. & Yap, A. S. Endocytosis, cadherins and tissue dynamics.
1294 *Traffic* **21**, 268-273, doi:10.1111/tra.12721 (2020).
1295 12 Ladoux, B., Mege, R. M. & Trepat, X. Front-Rear Polarization by Mechanical Cues:
1296 From Single Cells to Tissues. *Trends Cell Biol* **26**, 420-433,
1297 doi:10.1016/j.tcb.2016.02.002 (2016).
1298 13 Gonzalez-Gaitan, M. & Julicher, F. The role of endocytosis during morphogenetic
1299 signaling. *Cold Spring Harb Perspect Biol* **6**, a016881,
1300 doi:10.1101/cshperspect.a016881 (2014).
1301 14 Mettlen, M. *et al.* Endocytic accessory proteins are functionally distinguished by
1302 their differential effects on the maturation of clathrin-coated pits. *Mol Biol Cell*
1303 **20**, 3251-3260, doi:10.1091/mbc.E09-03-0256 (2009).
1304 15 Johannes, L., Parton, R. G., Bassereau, P. & Mayor, S. Building endocytic pits
1305 without clathrin. *Nat Rev Mol Cell Biol* **16**, 311-321, doi:10.1038/nrm3968 (2015).
1306 16 Ferreira, A. P. A. & Boucrot, E. Mechanisms of Carrier Formation during Clathrin-
1307 Independent Endocytosis. *Trends Cell Biol* **28**, 188-200,
1308 doi:10.1016/j.tcb.2017.11.004 (2018).
1309 17 Azarnia Tehran, D., Lopez-Hernandez, T. & Maritzen, T. Endocytic Adaptor
1310 Proteins in Health and Disease: Lessons from Model Organisms and Human
1311 Mutations. *Cells* **8**, doi:10.3390/cells8111345 (2019).
1312 18 Khan, I. & Steeg, P. S. Endocytosis: a pivotal pathway for regulating metastasis. *Br*
1313 *J Cancer*, doi:10.1038/s41416-020-01179-8 (2020).

1314 19 Martello, A., Platt, F. M. & Eden, E. R. Staying in touch with the endocytic
1315 network: The importance of contacts for cholesterol transport. *Traffic* **21**, 354-
1316 363, doi:10.1111/tra.12726 (2020).
1317 20 Wu, H., Carvalho, P. & Voeltz, G. K. Here, there, and everywhere: The importance
1318 of ER membrane contact sites. *Science* **361**, doi:10.1126/science.aan5835 (2018).
1319 21 Scorrano, L. *et al.* Coming together to define membrane contact sites. *Nat*
1320 *Commun* **10**, 1287, doi:10.1038/s41467-019-09253-3 (2019).
1321 22 Kaempf, N. & Maritzen, T. Safeguards of Neurotransmission: Endocytic Adaptors
1322 as Regulators of Synaptic Vesicle Composition and Function. *Front Cell Neurosci*
1323 **11**, 320, doi:10.3389/fncel.2017.00320 (2017).
1324 23 Saheki, Y. & De Camilli, P. Synaptic vesicle endocytosis. *Cold Spring Harb Perspect*
1325 *Biol* **4**, a005645, doi:10.1101/cshperspect.a005645 (2012).
1326 24 Soykan, T., Maritzen, T. & Haucke, V. Modes and mechanisms of synaptic vesicle
1327 recycling. *Curr Opin Neurobiol* **39**, 17-23, doi:10.1016/j.conb.2016.03.005 (2016).
1328 25 Moreno-Layseca, P., Icha, J., Hamidi, H. & Ivaska, J. Integrin trafficking in cells
1329 and tissues. *Nat Cell Biol* **21**, 122-132, doi:10.1038/s41556-018-0223-z (2019).
1330 26 Bruser, L. & Bogdan, S. Adherens Junctions on the Move-Membrane Trafficking
1331 of E-Cadherin. *Cold Spring Harb Perspect Biol* **9**,
1332 doi:10.1101/cshperspect.a029140 (2017).
1333 27 Nino, C. A., Sala, S. & Polo, S. When ubiquitin meets E-cadherin: Plasticity of the
1334 epithelial cellular barrier. *Semin Cell Dev Biol* **93**, 136-144,
1335 doi:10.1016/j.semcdb.2018.12.005 (2019).
1336 28 Lampe, M., Vassilopoulos, S. & Merrifield, C. Clathrin coated pits, plaques and
1337 adhesion. *J Struct Biol* **196**, 48-56, doi:10.1016/j.jsb.2016.07.009 (2016).
1338 29 De Deyne, P. G. *et al.* The vitronectin receptor associates with clathrin-coated
1339 membrane domains via the cytoplasmic domain of its beta5 subunit. *J Cell Sci*
1340 **111 (Pt 18)**, 2729-2740 (1998).
1341 30 Heuser, J. Three-dimensional visualization of coated vesicle formation in
1342 fibroblasts. *J Cell Biol* **84**, 560-583, doi:10.1083/jcb.84.3.560 (1980).
1343 31 Maupin, P. & Pollard, T. D. Improved preservation and staining of HeLa cell actin
1344 filaments, clathrin-coated membranes, and other cytoplasmic structures by
1345 tannic acid-glutaraldehyde-saponin fixation. *J Cell Biol* **96**, 51-62,
1346 doi:10.1083/jcb.96.1.51 (1983).
1347 32 Saffarian, S., Cocucci, E. & Kirchhausen, T. Distinct dynamics of endocytic
1348 clathrin-coated pits and coated plaques. *PLoS Biol* **7**, e1000191,
1349 doi:10.1371/journal.pbio.1000191 (2009).
1350 33 Baschieri, F. *et al.* Frustrated endocytosis controls contractility-independent
1351 mechanotransduction at clathrin-coated structures. *Nat Commun* **9**, 3825,
1352 doi:10.1038/s41467-018-06367-y (2018).
1353 **This paper describes a function for clathrin-coated plaques as contractility-**
1354 **independent mechanosensitive structures that assemble with increasing**
1355 **substrate rigidity and that serve as platforms for receptor tyrosine kinase**
1356 **signaling.**
1357 34 Lock, J. G. *et al.* Clathrin-containing adhesion complexes. *J Cell Biol* **218**, 2086-
1358 2095, doi:10.1083/jcb.201811160 (2019).

1359 35 Kirchhausen, T., Owen, D. & Harrison, S. C. Molecular structure, function, and
1360 dynamics of clathrin-mediated membrane traffic. *Cold Spring Harb Perspect Biol*
1361 **6**, a016725, doi:10.1101/cshperspect.a016725 (2014).
1362 36 Mettlen, M., Chen, P. H., Srinivasan, S., Danuser, G. & Schmid, S. L. Regulation of
1363 Clathrin-Mediated Endocytosis. *Annu Rev Biochem* **87**, 871-896,
1364 doi:10.1146/annurev-biochem-062917-012644 (2018).
1365 37 Antonny, B. *et al.* Membrane fission by dynamin: what we know and what we
1366 need to know. *EMBO J* **35**, 2270-2284, doi:10.15252/embj.201694613 (2016).
1367 38 Ramachandran, R. & Schmid, S. L. The dynamin superfamily. *Curr Biol* **28**, R411-
1368 R416, doi:10.1016/j.cub.2017.12.013 (2018).
1369 39 Kaksonen, M. & Roux, A. Mechanisms of clathrin-mediated endocytosis. *Nat Rev*
1370 *Mol Cell Biol* **19**, 313-326, doi:10.1038/nrm.2017.132 (2018).
1371 40 Dambournet, D. *et al.* Genome-edited human stem cells expressing fluorescently
1372 labeled endocytic markers allow quantitative analysis of clathrin-mediated
1373 endocytosis during differentiation. *J Cell Biol* **217**, 3301-3311,
1374 doi:10.1083/jcb.201710084 (2018).
1375 **Using genome-edited human embryonic stem cells to derive isogenic**
1376 **fibroblasts and neuronal progenitors, the authors show that the levels of**
1377 **expression of the endocytic adaptor AP2 are cell context-regulated and that**
1378 **this impinges on CME dynamics.**
1379 41 Hanyaloglu, A. C. & von Zastrow, M. Regulation of GPCRs by endocytic
1380 membrane trafficking and its potential implications. *Annu Rev Pharmacol Toxicol*
1381 **48**, 537-568, doi:10.1146/annurev.pharmtox.48.113006.094830 (2008).
1382 42 Puthenveedu, M. A. & von Zastrow, M. Cargo regulates clathrin-coated pit
1383 dynamics. *Cell* **127**, 113-124, doi:10.1016/j.cell.2006.08.035 (2006).
1384 43 Henry, A. G. *et al.* Regulation of endocytic clathrin dynamics by cargo
1385 ubiquitination. *Dev Cell* **23**, 519-532, doi:10.1016/j.devcel.2012.08.003 (2012).
1386 44 Soohoo, A. L. & Puthenveedu, M. A. Divergent modes for cargo-mediated control
1387 of clathrin-coated pit dynamics. *Mol Biol Cell* **24**, 1725-1734, S1721-1712,
1388 doi:10.1091/mbc.E12-07-0550 (2013).
1389 45 Eichel, K., Jullie, D. & von Zastrow, M. beta-Arrestin drives MAP kinase signalling
1390 from clathrin-coated structures after GPCR dissociation. *Nat Cell Biol* **18**, 303-
1391 310, doi:10.1038/ncb3307 (2016).
1392 46 Eichel, K. *et al.* Catalytic activation of beta-arrestin by GPCRs. *Nature* **557**, 381-
1393 386, doi:10.1038/s41586-018-0079-1 (2018).
1394 **This study demonstrates an additional mechanism of β-arrestin activation,**
1395 **which does not require a stable GPCR–β-arrestin binding and promotes the**
1396 **accumulation of β-arrestin in clathrin-coated pits after dissociation from the**
1397 **GPCR, leading to ERK signalling.**
1398 47 Latorraca, N. R. *et al.* Molecular mechanism of GPCR-mediated arrestin
1399 activation. *Nature* **557**, 452-456, doi:10.1038/s41586-018-0077-3 (2018).
1400 **The mechanism of receptor-mediated arrestin activation is herein investigated**
1401 **through atomic-level simulations, revealing that, in the absence of a receptor,**
1402 **arrestin frequently adopts active conformations, which may explain why**
1403 **arrestin may remain active also after receptor dissociation (as shown by Eichel**
1404 **et al. (2018)).**

48 Huang, F., Khvorova, A., Marshall, W. & Sorkin, A. Analysis of clathrin-mediated endocytosis of epidermal growth factor receptor by RNA interference. *J Biol Chem* **279**, 16657-16661, doi:10.1074/jbc.C400046200 (2004).

49 Motley, A., Bright, N. A., Seaman, M. N. & Robinson, M. S. Clathrin-mediated endocytosis in AP-2-depleted cells. *J Cell Biol* **162**, 909-918, doi:10.1083/jcb.200305145 (2003).

50 Hinrichsen, L., Harborth, J., Andrees, L., Weber, K. & Ungewickell, E. J. Effect of clathrin heavy chain- and alpha-adaptin-specific small inhibitory RNAs on endocytic accessory proteins and receptor trafficking in HeLa cells. *J Biol Chem* **278**, 45160-45170, doi:10.1074/jbc.M307290200 (2003).

51 Pascolutti, R. *et al.* Molecularly Distinct Clathrin-Coated Pits Differentially Impact EGFR Fate and Signaling. *Cell Rep* **27**, 3049-3061 e3046, doi:10.1016/j.celrep.2019.05.017 (2019).

52 Ko, G. *et al.* Selective high-level expression of epsin 3 in gastric parietal cells, where it is localized at endocytic sites of apical canaliculi. *Proc Natl Acad Sci U S A* **107**, 21511-21516, doi:10.1073/pnas.1016390107 (2010).

53 Schiano Lomoriello, I. *et al.* A self-sustaining endocytic-based loop promotes breast cancer plasticity leading to aggressiveness and pro-metastatic behavior. *Nat Commun* **11**, 3020, doi:10.1038/s41467-020-16836-y (2020).

This study shows that the endocytic protein EPN3 is an oncogene with prognostic relevance in breast cancer and that it drives breast tumorigenesis through the induction of E-cadherin endocytosis, EMT and invasive behaviour.

54 Sen, A., Madhivanan, K., Mukherjee, D. & Aguilar, R. C. The epsin protein family: coordinators of endocytosis and signaling. *Biomol Concepts* **3**, 117-126, doi:10.1515/bmc-2011-0060 (2012).

55 Kazazic, M. *et al.* Epsin 1 is involved in recruitment of ubiquitinated EGF receptors into clathrin-coated pits. *Traffic* **10**, 235-245, doi:10.1111/j.1600-0854.2008.00858.x (2009).

56 Sigismund, S. *et al.* Clathrin-independent endocytosis of ubiquitinated cargos. *Proc Natl Acad Sci U S A* **102**, 2760-2765, doi:10.1073/pnas.0409817102 (2005).

57 Chang, B. *et al.* Epsin is required for Dishevelled stability and Wnt signalling activation in colon cancer development. *Nat Commun* **6**, 6380, doi:10.1038/ncomms7380 (2015).

58 Tian, X., Hansen, D., Schedl, T. & Skeath, J. B. Epsin potentiates Notch pathway activity in Drosophila and C. elegans. *Development* **131**, 5807-5815, doi:10.1242/dev.01459 (2004).

59 Langridge, P. D. & Struhl, G. Epsin-Dependent Ligand Endocytosis Activates Notch by Force. *Cell* **171**, 1383-1396 e1312, doi:10.1016/j.cell.2017.10.048 (2017).

60 Pasula, S. *et al.* Endothelial epsin deficiency decreases tumor growth by enhancing VEGF signaling. *J Clin Invest* **122**, 4424-4438, doi:10.1172/JCI64537 (2012).

61 Spradling, K. D., McDaniel, A. E., Lohi, J. & Pilcher, B. K. Epsin 3 is a novel extracellular matrix-induced transcript specific to wounded epithelia. *J Biol Chem* **276**, 29257-29267, doi:10.1074/jbc.M101663200 (2001).

62 Ferguson, S. M. *et al.* A selective activity-dependent requirement for dynamin 1 in synaptic vesicle endocytosis. *Science* **316**, 570-574, doi:10.1126/science.1140621 (2007).

1452 63 Ferguson, S. M. *et al.* Coordinated actions of actin and BAR proteins upstream of
1453 dynamin at endocytic clathrin-coated pits. *Dev Cell* **17**, 811-822,
1454 doi:10.1016/j.devcel.2009.11.005 (2009).
1455 64 Liu, Y. W., Surka, M. C., Schroeter, T., Lukiyanchuk, V. & Schmid, S. L. Isoform and
1456 splice-variant specific functions of dynamin-2 revealed by analysis of conditional
1457 knock-out cells. *Mol Biol Cell* **19**, 5347-5359, doi:10.1091/mbc.E08-08-0890
1458 (2008).
1459 65 Reis, C. R. *et al.* Crosstalk between Akt/GSK3beta signaling and dynamin-1
1460 regulates clathrin-mediated endocytosis. *EMBO J* **34**, 2132-2146,
1461 doi:10.15252/embj.201591518 (2015).
1462 66 Srinivasan, S. *et al.* A noncanonical role for dynamin-1 in regulating early stages
1463 of clathrin-mediated endocytosis in non-neuronal cells. *PLoS Biol* **16**, e2005377,
1464 doi:10.1371/journal.pbio.2005377 (2018).
1465 **Shows that although highly enriched in neurons, Dynamin-1 is expressed in**
1466 **non-neuronal cells, but inactivated via phosphorylation by GSK3β, and that it**
1467 **becomes activated downstream of EGFR signalling to regulate dynamics of**
1468 **clathrin-coated pits.**
1469 67 Loerke, D. *et al.* Cargo and dynamin regulate clathrin-coated pit maturation. *PLoS*
1470 *Biol* **7**, e57, doi:10.1371/journal.pbio.1000057 (2009).
1471 68 Clayton, E. L. *et al.* Dynamin I phosphorylation by GSK3 controls activity-
1472 dependent bulk endocytosis of synaptic vesicles. *Nat Neurosci* **13**, 845-851,
1473 doi:10.1038/nn.2571 (2010).
1474 69 Meng, J. Distinct functions of dynamin isoforms in tumorigenesis and their
1475 potential as therapeutic targets in cancer. *Oncotarget* **8**, 41701-41716,
1476 doi:10.18632/oncotarget.16678 (2017).
1477 70 Gong, C. *et al.* Dynamin2 downregulation delays EGFR endocytic trafficking and
1478 promotes EGFR signaling and invasion in hepatocellular carcinoma. *Am J Cancer*
1479 *Res* **5**, 702-713 (2015).
1480 71 Ezratty, E. J., Bertaux, C., Marcantonio, E. E. & Gundersen, G. G. Clathrin
1481 mediates integrin endocytosis for focal adhesion disassembly in migrating cells. *J*
1482 *Cell Biol* **187**, 733-747, doi:10.1083/jcb.200904054 (2009).
1483 72 Burton, K. M. *et al.* Dynamin 2 interacts with alpha-actinin 4 to drive tumor cell
1484 invasion. *Mol Biol Cell* **31**, 439-451, doi:10.1091/mbc.E19-07-0395 (2020).
1485 73 Bhave, M., Mettlen, M., Wang, X. & Schmid, S. L. Early and non-redundant
1486 functions of dynamin isoforms in clathrin-mediated endocytosis. *Mol Biol Cell*,
1487 mbcE20060363, doi:10.1091/mbc.E20-06-0363 (2020).
1488 74 Reis, C. R., Chen, P. H., Bendris, N. & Schmid, S. L. TRAIL-death receptor
1489 endocytosis and apoptosis are selectively regulated by dynamin-1 activation.
1490 *Proc Natl Acad Sci U S A* **114**, 504-509, doi:10.1073/pnas.1615072114 (2017).
1491 75 Parton, R. G. *et al.* Caveolae: The FAQs. *Traffic*, doi:10.1111/tra.12689 (2019).
1492 76 Parton, R. G., McMahon, K. A. & Wu, Y. Caveolae: Formation, dynamics, and
1493 function. *Curr Opin Cell Biol* **65**, 8-16, doi:10.1016/j.ceb.2020.02.001 (2020).
1494 77 Sabharanjak, S., Sharma, P., Parton, R. G. & Mayor, S. GPI-anchored proteins are
1495 delivered to recycling endosomes via a distinct cdc42-regulated, clathrin-
1496 independent pinocytic pathway. *Dev Cell* **2**, 411-423, doi:10.1016/s1534-
1497 5807(02)00145-4 (2002).

1498 78 Kirkham, M. *et al.* Ultrastructural identification of uncoated caveolin-
1499 independent early endocytic vehicles. *J Cell Biol* **168**, 465-476,
1500 doi:10.1083/jcb.200407078 (2005).
1501 79 Holst, M. R. *et al.* Clathrin-Independent Endocytosis Suppresses Cancer Cell
1502 Blebbing and Invasion. *Cell Rep* **20**, 1893-1905, doi:10.1016/j.celrep.2017.08.006
1503 (2017).
1504 80 Howes, M. T. *et al.* Clathrin-independent carriers form a high capacity endocytic
1505 sorting system at the leading edge of migrating cells. *J Cell Biol* **190**, 675-691,
1506 doi:10.1083/jcb.201002119 (2010).
1507 81 Thottacherry, J. J. *et al.* Mechanochemical feedback control of dynamin
1508 independent endocytosis modulates membrane tension in adherent cells. *Nat*
1509 *Commun* **9**, 4217, doi:10.1038/s41467-018-06738-5 (2018).
1510 **This study describes a role for CLIC/GEEC endocytosis as a critical regulator of**
1511 **membrane tension in adherent cells, and dissects the downstream molecular**
1512 **mechanism, which involves vinculin as a mechanotransducer at focal adhesion**
1513 **sites.**
1514 82 Goldmann, W. H. Role of vinculin in cellular mechanotransduction. *Cell Biol Int*
1515 **40**, 241-256, doi:10.1002/cbin.10563 (2016).
1516 83 del Pozo, M. A. *et al.* Phospho-caveolin-1 mediates integrin-regulated membrane
1517 domain internalization. *Nat Cell Biol* **7**, 901-908, doi:10.1038/ncb1293 (2005).
1518 84 Boucrot, E. *et al.* Endophilin marks and controls a clathrin-independent endocytic
1519 pathway. *Nature* **517**, 460-465, doi:10.1038/nature14067 (2015).
1520 85 Casamento, A. & Boucrot, E. Molecular mechanism of Fast Endophilin-Mediated
1521 Endocytosis. *Biochem J* **477**, 2327-2345, doi:10.1042/BCJ20190342 (2020).
1522 86 Sigismund, S. *et al.* Clathrin-mediated internalization is essential for sustained
1523 EGFR signaling but dispensable for degradation. *Dev Cell* **15**, 209-219,
1524 doi:10.1016/j.devcel.2008.06.012 (2008).
1525 87 Caldieri, G. *et al.* Reticulon 3-dependent ER-PM contact sites control EGFR
1526 nonclathrin endocytosis. *Science* **356**, 617-624, doi:10.1126/science.aah6152
1527 (2017).
1528 88 Ghosh, S., Marrocco, I. & Yarden, Y. Roles for receptor tyrosine kinases in tumor
1529 progression and implications for cancer treatment. *Adv Cancer Res* **147**, 1-57,
1530 doi:10.1016/bs.acr.2020.04.002 (2020).
1531 89 Schlessinger, J. Receptor tyrosine kinases: legacy of the first two decades. *Cold*
1532 *Spring Harb Perspect Biol* **6**, doi:10.1101/cshperspect.a008912 (2014).
1533 90 Lamaze, C. *et al.* Interleukin 2 receptors and detergent-resistant membrane
1534 domains define a clathrin-independent endocytic pathway. *Mol Cell* **7**, 661-671,
1535 doi:10.1016/s1097-2765(01)00212-x (2001).
1536 91 Hemar, A. *et al.* Endocytosis of interleukin 2 receptors in human T lymphocytes:
1537 distinct intracellular localization and fate of the receptor alpha, beta, and gamma
1538 chains. *J Cell Biol* **129**, 55-64, doi:10.1083/jcb.129.1.55 (1995).
1539 92 Sehat, B., Andersson, S., Girnita, L. & Larsson, O. Identification of c-Cbl as a new
1540 ligase for insulin-like growth factor-I receptor with distinct roles from Mdm2 in
1541 receptor ubiquitination and endocytosis. *Cancer Res* **68**, 5669-5677,
1542 doi:10.1158/0008-5472.CAN-07-6364 (2008).
1543 93 Salani, B. *et al.* IGF-IR internalizes with Caveolin-1 and PTRF/Cavin in HaCat cells.
1544 *PLoS One* **5**, e14157, doi:10.1371/journal.pone.0014157 (2010).

1545 94 De Donatis, A. *et al.* Proliferation versus migration in platelet-derived growth
1546 factor signaling: the key role of endocytosis. *J Biol Chem* **283**, 19948-19956,
1547 doi:10.1074/jbc.M709428200 (2008).
1548 95 Jastrzebski, K. *et al.* Multiple routes of endocytic internalization of PDGFRbeta
1549 contribute to PDGF-induced STAT3 signaling. *J Cell Sci* **130**, 577-589,
1550 doi:10.1242/jcs.191213 (2017).
1551 96 Sadowski, L. *et al.* Dynamin inhibitors impair endocytosis and mitogenic signaling
1552 of PDGF. *Traffic* **14**, 725-736, doi:10.1111/tra.12061 (2013).
1553 97 Basagiannis, D. *et al.* VEGF induces signalling and angiogenesis by directing
1554 VEGFR2 internalisation through macropinocytosis. *J Cell Sci* **129**, 4091-4104,
1555 doi:10.1242/jcs.188219 (2016).
1556 98 Genet, G. *et al.* Endophilin-A2 dependent VEGFR2 endocytosis promotes
1557 sprouting angiogenesis. *Nat Commun* **10**, 2350, doi:10.1038/s41467-019-10359-x
1558 (2019).
1559 99 Nakayama, M. *et al.* Spatial regulation of VEGF receptor endocytosis in
1560 angiogenesis. *Nat Cell Biol* **15**, 249-260, doi:10.1038/ncb2679 (2013).
1561 100 Sawamiphak, S. *et al.* Ephrin-B2 regulates VEGFR2 function in developmental and
1562 tumour angiogenesis. *Nature* **465**, 487-491, doi:10.1038/nature08995 (2010).
1563 101 Marques, P. E., Grinstein, S. & Freeman, S. A. SnapShot:Macropinocytosis. *Cell*
1564 **169**, 766-766 e761, doi:10.1016/j.cell.2017.04.031 (2017).
1565 102 Lin, X. P., Mintern, J. D. & Gleeson, P. A. Macropinocytosis in Different Cell Types:
1566 Similarities and Differences. *Membranes (Basel)* **10**,
1567 doi:10.3390/membranes10080177 (2020).
1568 103 Bar-Sagi, D. & Feramisco, J. R. Induction of membrane ruffling and fluid-phase
1569 pinocytosis in quiescent fibroblasts by ras proteins. *Science* **233**, 1061-1068,
1570 doi:10.1126/science.3090687 (1986).
1571 104 Porat-Shliom, N., Kloog, Y. & Donaldson, J. G. A unique platform for H-Ras
1572 signaling involving clathrin-independent endocytosis. *Mol Biol Cell* **19**, 765-775,
1573 doi:10.1091/mbc.e07-08-0841 (2008).
1574 105 Walsh, A. B. & Bar-Sagi, D. Differential activation of the Rac pathway by Ha-Ras
1575 and K-Ras. *J Biol Chem* **276**, 15609-15615, doi:10.1074/jbc.M010573200 (2001).
1576 106 Recouvreux, M. V. & Commisso, C. Macropinocytosis: A Metabolic Adaptation to
1577 Nutrient Stress in Cancer. *Front Endocrinol (Lausanne)* **8**, 261,
1578 doi:10.3389/fendo.2017.00261 (2017).
1579 107 Kim, S. M. *et al.* PTEN Deficiency and AMPK Activation Promote Nutrient
1580 Scavenging and Anabolism in Prostate Cancer Cells. *Cancer Discov* **8**, 866-883,
1581 doi:10.1158/2159-8290.CD-17-1215 (2018).
1582 108 Jayashankar, V. & Edinger, A. L. Macropinocytosis confers resistance to therapies
1583 targeting cancer anabolism. *Nat Commun* **11**, 1121, doi:10.1038/s41467-020-
1584 14928-3 (2020).
1585 **This study establishes necrocytosis as a mechanism of drug resistance,**
1586 **demonstrating its role in supplying amino acids, sugars, fatty acids and**
1587 **nucleotides for biosynthesis, and evidencing that it confers resistance to**
1588 **therapies targeting anabolic pathways in a cell context-dependent manner.**
1589 109 Jayashankar, V., Finicle, B. T. & Edinger, A. L. Starving PTEN-deficient prostate
1590 cancer cells thrive under nutrient stress by scavenging corpses for their supper.
1591 *Mol Cell Oncol* **5**, e1472060, doi:10.1080/23723556.2018.1472060 (2018).

1592 110 Norris, A. & Grant, B. D. Endosomal microdomains: Formation and function. *Curr*
1593 *Opin Cell Biol* **65**, 86-95, doi:10.1016/j.ceb.2020.02.018 (2020).
1594 111 Eichel, K. & von Zastrow, M. Subcellular Organization of GPCR Signaling. *Trends*
1595 *Pharmacol Sci* **39**, 200-208, doi:10.1016/j.tips.2017.11.009 (2018).
1596 112 Irannejad, R. & von Zastrow, M. GPCR signaling along the endocytic pathway.
1597 *Curr Opin Cell Biol* **27**, 109-116, doi:10.1016/j.ceb.2013.10.003 (2014).
1598 113 Jha, A., van Zanten, T. S., Philippe, J. M., Mayor, S. & Lecuit, T. Quantitative
1599 Control of GPCR Organization and Signaling by Endocytosis in Epithelial
1600 Morphogenesis. *Curr Biol* **28**, 1570-1584 e1576, doi:10.1016/j.cub.2018.03.068
1601 (2018).
1602 **Shows that in the *D. melanogaster* embryo, the dynamic partitioning of active**
1603 **GPCRs at the plasma membrane or in plasma membrane invaginations by**
1604 **endocytosis creates platforms for RHO1 signaling and MyoII activation, which**
1605 **regulate epithelial morphogenesis.**
1606 114 Kerridge, S. *et al.* Modular activation of Rho1 by GPCR signalling imparts
1607 polarized myosin II activation during morphogenesis. *Nat Cell Biol* **18**, 261-270,
1608 doi:10.1038/ncb3302 (2016).
1609 115 Irannejad, R. *et al.* Functional selectivity of GPCR-directed drug action through
1610 location bias. *Nat Chem Biol* **13**, 799-806, doi:10.1038/nchembio.2389 (2017).
1611 **In this study, the human β1-adrenergic receptor is shown to induce cAMP**
1612 **signalling from the Golgi apparatus, leading authors to propose 'location bias'**
1613 **as a new principle for achieving functional selectivity of GPCR-directed drug**
1614 **action.**
1615 116 Godbole, A., Lyga, S., Lohse, M. J. & Calebiro, D. Internalized TSH receptors en
1616 route to the TGN induce local Gs-protein signaling and gene transcription. *Nat*
1617 *Commun* **8**, 443, doi:10.1038/s41467-017-00357-2 (2017).
1618 117 Boivin, B., Vaniotis, G., Allen, B. G. & Hebert, T. E. G protein-coupled receptors in
1619 and on the cell nucleus: a new signaling paradigm? *J Recept Signal Transduct Res*
1620 **28**, 15-28, doi:10.1080/10799890801941889 (2008).
1621 118 Calebiro, D. *et al.* Persistent cAMP-signals triggered by internalized G-protein-
1622 coupled receptors. *PLoS Biol* **7**, e1000172, doi:10.1371/journal.pbio.1000172
1623 (2009).
1624 119 Inda, C. *et al.* Different cAMP sources are critically involved in G protein-coupled
1625 receptor CRHR1 signaling. *J Cell Biol* **214**, 181-195, doi:10.1083/jcb.201512075
1626 (2016).
1627 120 Lazar, A. M. *et al.* G protein-regulated endocytic trafficking of adenylyl cyclase
1628 type 9. *Elife* **9**, doi:10.7554/eLife.58039 (2020).
1629 121 Tsvetanova, N. G. & von Zastrow, M. Spatial encoding of cyclic AMP signaling
1630 specificity by GPCR endocytosis. *Nat Chem Biol* **10**, 1061-1065,
1631 doi:10.1038/nchembio.1665 (2014).
1632 122 Ritter, S. L. & Hall, R. A. Fine-tuning of GPCR activity by receptor-interacting
1633 proteins. *Nat Rev Mol Cell Biol* **10**, 819-830, doi:10.1038/nrm2803 (2009).
1634 123 Weinberg, Z. Y. & Puthenveedu, M. A. Regulation of G protein-coupled receptor
1635 signaling by plasma membrane organization and endocytosis. *Traffic* **20**, 121-
1636 129, doi:10.1111/tra.12628 (2019).

1637 124 Heuninck, J. *et al.* Context-Dependent Signaling of CXC Chemokine Receptor 4
1638 and Atypical Chemokine Receptor 3. *Mol Pharmacol* **96**, 778-793,
1639 doi:10.1124/mol.118.115477 (2019).
1640 125 Hauser, A. S. *et al.* Pharmacogenomics of GPCR Drug Targets. *Cell* **172**, 41-54 e19,
1641 doi:10.1016/j.cell.2017.11.033 (2018).
1642 126 Retamal, J. S., Ramirez-Garcia, P. D., Shenoy, P. A., Poole, D. P. & Veldhuis, N. A.
1643 Internalized GPCRs as Potential Therapeutic Targets for the Management of Pain.
1644 *Front Mol Neurosci* **12**, 273, doi:10.3389/fnmol.2019.00273 (2019).
1645 127 Jimenez-Vargas, N. N. *et al.* Protease-activated receptor-2 in endosomes signals
1646 persistent pain of irritable bowel syndrome. *Proc Natl Acad Sci U S A* **115**, E7438-
1647 E7447, doi:10.1073/pnas.1721891115 (2018).
1648 128 Jimenez-Vargas, N. N. *et al.* Endosomal signaling of delta opioid receptors is an
1649 endogenous mechanism and therapeutic target for relief from inflammatory
1650 pain. *Proc Natl Acad Sci U S A* **117**, 15281-15292, doi:10.1073/pnas.2000500117
1651 (2020).
1652 129 Ramirez-Garcia, P. D. *et al.* A pH-responsive nanoparticle targets the neurokinin 1
1653 receptor in endosomes to prevent chronic pain. *Nat Nanotechnol* **14**, 1150-1159,
1654 doi:10.1038/s41565-019-0568-x (2019).
1655 130 Arakaki, A. K. S., Pan, W. A. & Trejo, J. GPCRs in Cancer: Protease-Activated
1656 Receptors, Endocytic Adaptors and Signaling. *Int J Mol Sci* **19**,
1657 doi:10.3390/ijms19071886 (2018).
1658 131 Dorsam, R. T. & Gutkind, J. S. G-protein-coupled receptors and cancer. *Nat Rev*
1659 *Cancer* **7**, 79-94, doi:10.1038/nrc2069 (2007).
1660 132 Gad, A. A. & Balenga, N. The Emerging Role of Adhesion GPCRs in Cancer. *ACS*
1661 *Pharmacol Transl Sci* **3**, 29-42, doi:10.1021/acsptsci.9b00093 (2020).
1662 133 Usman, S., Khawer, M., Rafique, S., Naz, Z. & Saleem, K. The current status of
1663 anti-GPCR drugs against different cancers. *Journal of Pharmaceutical Analysis* **10**,
1664 517-521, doi:https://doi.org/10.1016/j.jpha.2020.01.001 (2020).
1665 134 Lavoie, H., Gagnon, J. & Therrien, M. ERK signalling: a master regulator of cell
1666 behaviour, life and fate. *Nat Rev Mol Cell Biol* **21**, 607-632, doi:10.1038/s41580-
1667 020-0255-7 (2020).
1668 135 Schiefermeier, N., Teis, D. & Huber, L. A. Endosomal signaling and cell migration.
1669 *Curr Opin Cell Biol* **23**, 615-620, doi:10.1016/j.ceb.2011.04.001 (2011).
1670 136 Matsubayashi, Y., Ebisuya, M., Honjoh, S. & Nishida, E. ERK activation propagates
1671 in epithelial cell sheets and regulates their migration during wound healing. *Curr*
1672 *Biol* **14**, 731-735, doi:10.1016/j.cub.2004.03.060 (2004).
1673 137 Aoki, K. *et al.* Propagating Wave of ERK Activation Orients Collective Cell
1674 Migration. *Dev Cell* **43**, 305-317 e305, doi:10.1016/j.devcel.2017.10.016 (2017).
1675 138 Malinverno, C. *et al.* Endocytic reawakening of motility in jammed epithelia. *Nat*
1676 *Mater* **16**, 587-596, doi:10.1038/nmat4848 (2017).
1677 139 Villasenor, R., Nonaka, H., Del Conte-Zerial, P., Kalaidzidis, Y. & Zerial, M.
1678 Regulation of EGFR signal transduction by analogue-to-digital conversion in
1679 endosomes. *Elife* **4**, doi:10.7554/eLife.06156 (2015).
1680 140 Cullen, P. J. & Steinberg, F. To degrade or not to degrade: mechanisms and
1681 significance of endocytic recycling. *Nat Rev Mol Cell Biol* **19**, 679-696,
1682 doi:10.1038/s41580-018-0053-7 (2018).

1683 141 Zerial, M. & McBride, H. Rab proteins as membrane organizers. *Nat Rev Mol Cell*
1684 *Biol* **2**, 107-117, doi:10.1038/35052055 (2001).
1685 142 Tebar, F., Enrich, C., Rentero, C. & Grewal, T. GTPases Rac1 and Ras Signaling
1686 from Endosomes. *Prog Mol Subcell Biol* **57**, 65-105, doi:10.1007/978-3-319-
1687 96704-2_3 (2018).
1688 143 Horiuchi, H. *et al.* A novel Rab5 GDP/GTP exchange factor complexed to
1689 Rabaptin-5 links nucleotide exchange to effector recruitment and function. *Cell*
1690 **90**, 1149-1159, doi:10.1016/s0092-8674(00)80380-3 (1997).
1691 144 Christoforidis, S. *et al.* Phosphatidylinositol-3-OH kinases are Rab5 effectors. *Nat*
1692 *Cell Biol* **1**, 249-252, doi:10.1038/12075 (1999).
1693 145 Christoforidis, S., McBride, H. M., Burgoyne, R. D. & Zerial, M. The Rab5 effector
1694 EEA1 is a core component of endosome docking. *Nature* **397**, 621-625,
1695 doi:10.1038/17618 (1999).
1696 146 Cezanne, A., Lauer, J., Solomatina, A., Sbalzarini, I. F. & Zerial, M. A non-linear
1697 system patterns Rab5 GTPase on the membrane. *Elife* **9**, doi:10.7554/eLife.54434
1698 (2020).
1699 **Using an in vitro reconstituted system with lipid bilayers, this study shows that**
1700 **positive feedback regulatory loops control RAB5 recruitment and activation on**
1701 **early endosomes, determining its patterning on endosomal membranes.**
1702 147 Murray, J. T., Panaretou, C., Stenmark, H., Miaczynska, M. & Backer, J. M. Role of
1703 Rab5 in the recruitment of hVps34/p150 to the early endosome. *Traffic* **3**, 416-
1704 427, doi:10.1034/j.1600-0854.2002.30605.x (2002).
1705 148 Edler, E. & Stein, M. Probing the druggability of membrane-bound Rab5 by
1706 molecular dynamics simulations. *J Enzyme Inhib Med Chem* **32**, 434-443,
1707 doi:10.1080/14756366.2016.1260564 (2017).
1708 149 Munzberg, E. & Stein, M. Structure and Dynamics of Mono- vs. Doubly Lipidated
1709 Rab5 in Membranes. *Int J Mol Sci* **20**, doi:10.3390/ijms20194773 (2019).
1710 150 Bucci, C. *et al.* Co-operative regulation of endocytosis by three Rab5 isoforms.
1711 *FEBS Lett* **366**, 65-71, doi:10.1016/0014-5793(95)00477-q (1995).
1712 151 Wainszelbaum, M. J., Proctor, B. M., Pontow, S. E., Stahl, P. D. & Barbieri, M. A.
1713 IL4/PGE2 induction of an enlarged early endosomal compartment in mouse
1714 macrophages is Rab5-dependent. *Exp Cell Res* **312**, 2238-2251,
1715 doi:10.1016/j.yexcr.2006.03.025 (2006).
1716 152 Chen, P. I., Kong, C., Su, X. & Stahl, P. D. Rab5 isoforms differentially regulate the
1717 trafficking and degradation of epidermal growth factor receptors. *J Biol Chem*
1718 **284**, 30328-30338, doi:10.1074/jbc.M109.034546 (2009).
1719 153 Bhattacharya, M. *et al.* IL-6 and IL-12 specifically regulate the expression of Rab5
1720 and Rab7 via distinct signaling pathways. *EMBO J* **25**, 2878-2888,
1721 doi:10.1038/sj.emboj.7601170 (2006).
1722 154 Goryachev, A. B. & Pokhilko, A. V. Dynamics of Cdc42 network embodies a
1723 Turing-type mechanism of yeast cell polarity. *FEBS Lett* **582**, 1437-1443,
1724 doi:10.1016/j.febslet.2008.03.029 (2008).
1725 155 Witte, K., Strickland, D. & Glotzer, M. Cell cycle entry triggers a switch between
1726 two modes of Cdc42 activation during yeast polarization. *Elife* **6**,
1727 doi:10.7554/eLife.26722 (2017).

1728 156 Zhou, Y. *et al.* Lipid-Sorting Specificity Encoded in K-Ras Membrane Anchor
1729 Regulates Signal Output. *Cell* **168**, 239-251 e216, doi:10.1016/j.cell.2016.11.059
1730 (2017).
1731 **Demonstration that clustering of K-RAS at the plasma membrane leads to the**
1732 **assembly of specific phospholipids into nanoclusters determining K-RAS**
1733 **signalling output.**
1734 157 Halatek, J., Brauns, F. & Frey, E. Self-organization principles of intracellular
1735 pattern formation. *Philos Trans R Soc Lond B Biol Sci* **373**,
1736 doi:10.1098/rstb.2017.0107 (2018).
1737 158 Goryachev, A. B. & Leda, M. Autoactivation of small GTPases by the GEF-effector
1738 positive feedback modules. *F1000Res* **8**, doi:10.12688/f1000research.20003.1
1739 (2019).
1740 159 Mellman, I. & Nelson, W. J. Coordinated protein sorting, targeting and
1741 distribution in polarized cells. *Nat Rev Mol Cell Biol* **9**, 833-845, doi:nrm2525
1742 [pii]10.1038/nrm2525 (2008).
1743 160 Datta, A., Bryant, D. M. & Mostov, K. E. Molecular regulation of lumen
1744 morphogenesis. *Curr Biol* **21**, R126-136, doi:10.1016/j.cub.2010.12.003 (2011).
1745 161 Jewett, C. E. & Prekeris, R. Insane in the apical membrane: Trafficking events
1746 mediating apicobasal epithelial polarity during tube morphogenesis. *Traffic*,
1747 doi:10.1111/tra.12579 (2018).
1748 162 Overeem, A. W., Bryant, D. M. & van, I. S. C. Mechanisms of apical-basal axis
1749 orientation and epithelial lumen positioning. *Trends Cell Biol* **25**, 476-485,
1750 doi:10.1016/j.tcb.2015.04.002 (2015).
1751 163 Gandalovicova, A., Vomastek, T., Rosel, D. & Brabek, J. Cell polarity signaling in
1752 the plasticity of cancer cell invasiveness. *Oncotarget* **7**, 25022-25049,
1753 doi:10.18632/oncotarget.7214 (2016).
1754 164 Roman-Fernandez, A. & Bryant, D. M. Complex Polarity: Building Multicellular
1755 Tissues Through Apical Membrane Traffic. *Traffic* **17**, 1244-1261,
1756 doi:10.1111/tra.12417 (2016).
1757 **This study shows that the unusual phospholipid PI(3,4)P2, together with**
1758 **PI(4,5)P2, is found apically enriched during the early phases of lumen**
1759 **formation and controls polarity establishment.**
1760 165 West, J. J. & Harris, T. J. Cadherin Trafficking for Tissue Morphogenesis: Control
1761 and Consequences. *Traffic* **17**, 1233-1243, doi:10.1111/tra.12407 (2016).
1762 166 Mrozowska, P. S. & Fukuda, M. Regulation of podocalyxin trafficking by Rab small
1763 GTPases in 2D and 3D epithelial cell cultures. *J Cell Biol* **213**, 355-369,
1764 doi:10.1083/jcb.201512024 (2016).
1765 167 Diaz-Diaz, C., Baonza, G. & Martin-Belmonte, F. The vertebrate epithelial apical
1766 junctional complex: Dynamic interplay between Rho GTPase activity and cell
1767 polarization processes. *Biochim Biophys Acta Biomembr* **1862**, 183398,
1768 doi:10.1016/j.bbamem.2020.183398 (2020).
1769 168 Bryant, D. M. & Mostov, K. E. From cells to organs: building polarized tissue. *Nat*
1770 *Rev Mol Cell Biol* **9**, 887-901, doi:10.1038/nrm2523 (2008).
1771 169 Nelson, W. J. Adaptation of core mechanisms to generate cell polarity. *Nature*
1772 **422**, 766-774, doi:10.1038/nature01602 (2003).
1773 170 Schluter, M. A. & Margolis, B. Apicobasal polarity in the kidney. *Exp Cell Res* **318**,
1774 1033-1039, doi:10.1016/j.yexcr.2012.02.028 (2012).

1775 171 Bryant, D. M. *et al.* A molecular network for de novo generation of the apical
1776 surface and lumen. *Nat Cell Biol* **12**, 1035-1045, doi:10.1038/ncb2106 (2010).
1777 172 Mangan, A. J. *et al.* Cingulin and actin mediate midbody-dependent apical lumen
1778 formation during polarization of epithelial cells. *Nat Commun* **7**, 12426,
1779 doi:10.1038/ncomms12426 (2016).
1780 173 Su, T. *et al.* A kinase cascade leading to Rab11-FIP5 controls transcytosis of the
1781 polymeric immunoglobulin receptor. *Nat Cell Biol* **12**, 1143-1153,
1782 doi:10.1038/ncb2118 (2010).
1783 174 Klinkert, K., Rocancourt, M., Houdusse, A. & Echard, A. Rab35 GTPase couples
1784 cell division with initiation of epithelial apico-basal polarity and lumen opening.
1785 *Nat Commun* **7**, 11166, doi:10.1038/ncomms11166 (2016).
1786 175 Kinoshita, R., Homma, Y. & Fukuda, M. Rab35-GEFs, DENND1A and folliculin
1787 differentially regulate podocalyxin trafficking in two- and three-dimensional
1788 epithelial cell cultures. *J Biol Chem*, doi:10.1074/jbc.RA119.011646 (2020).
1789 176 Willenborg, C. *et al.* Interaction between FIP5 and SNX18 regulates epithelial
1790 lumen formation. *J Cell Biol* **195**, 71-86, doi:10.1083/jcb.201011112 (2011).
1791 177 Roman-Fernandez, A. *et al.* The phospholipid PI(3,4)P2 is an apical identity
1792 determinant. *Nat Commun* **9**, 5041, doi:10.1038/s41467-018-07464-8 (2018).
1793 178 Martin-Belmonte, F. *et al.* PTEN-mediated apical segregation of
1794 phosphoinositides controls epithelial morphogenesis through Cdc42. *Cell* **128**,
1795 383-397, doi:10.1016/j.cell.2006.11.051 (2007).
1796 179 Bisi, S. *et al.* IRSp53 controls plasma membrane shape and polarized transport at
1797 the nascent lumen in epithelial tubules. *Nat Commun* **11**, 3516,
1798 doi:10.1038/s41467-020-17091-x (2020).
1799 **The I-BAR containing protein, IRSP53, is shown to be an early apical**
1800 **determinant that binds to RAB35 and facilitates the transport and the**
1801 **anchoring of podocalyxin to the apical membrane initiation site, where it also**
1802 **controls the integrity and the shape of the plasma membrane.**
1803 180 Zhang, Y. *et al.* Biomimetic niches reveal the minimal cues to trigger apical lumen
1804 formation in single hepatocytes. *Nat Mater*, doi:10.1038/s41563-020-0662-3
1805 (2020).
1806 **An elegant study that shows how the density and localization of cadherins,**
1807 **along the initial cell-to-cell contact, represent the minimal molecular and**
1808 **physical cues to trigger the development of asymmetric lateral hemilumen in**
1809 **hepatocytes.**
1810 181 Li, Q. *et al.* Extracellular matrix scaffolding guides lumen elongation by inducing
1811 anisotropic intercellular mechanical tension. *Nat Cell Biol* **18**, 311-318,
1812 doi:10.1038/ncb3310 (2016).
1813 182 Ferrari, A., Veligodskiy, A., Berge, U., Lucas, M. S. & Kroschewski, R. ROCK-
1814 mediated contractility, tight junctions and channels contribute to the conversion
1815 of a preapical patch into apical surface during isochoric lumen initiation. *J Cell Sci*
1816 **121**, 3649-3663, doi:10.1242/jcs.018648 (2008).
1817 183 Saito, Y., Desai, R. R. & Muthuswamy, S. K. Reinterpreting polarity and cancer:
1818 The changing landscape from tumor suppression to tumor promotion. *Biochim*
1819 *Biophys Acta Rev Cancer* **1869**, 103-116, doi:10.1016/j.bbcan.2017.12.001
1820 (2018).

1821 184 Vladar, E. K., Antic, D. & Axelrod, J. D. Planar cell polarity signaling: the
1822 developing cell's compass. *Cold Spring Harb Perspect Biol* **1**, a002964,
1823 doi:10.1101/cshperspect.a002964 (2009).
1824 185 Simons, M. & Mlodzik, M. Planar cell polarity signaling: from fly development to
1825 human disease. *Annu Rev Genet* **42**, 517-540,
1826 doi:10.1146/annurev.genet.42.110807.091432 (2008).
1827 186 Strutt, H. & Strutt, D. Asymmetric localisation of planar polarity proteins:
1828 Mechanisms and consequences. *Semin Cell Dev Biol* **20**, 957-963,
1829 doi:10.1016/j.semcdb.2009.03.006 (2009).
1830 187 Maung, S. M. & Jenny, A. Planar cell polarity in Drosophila. *Organogenesis* **7**,
1831 165-179, doi:10.4161/org.7.3.18143 (2011).
1832 188 Xie, Y., Miao, H. & Blankenship, J. T. Membrane trafficking in morphogenesis and
1833 planar polarity. *Traffic*, doi:10.1111/tra.12580 (2018).
1834 189 Butler, M. T. & Wallingford, J. B. Planar cell polarity in development and disease.
1835 *Nat Rev Mol Cell Biol* **18**, 375-388, doi:10.1038/nrm.2017.11 (2017).
1836 190 Voiculescu, O., Bertocchini, F., Wolpert, L., Keller, R. E. & Stern, C. D. The amniote
1837 primitive streak is defined by epithelial cell intercalation before gastrulation.
1838 *Nature* **449**, 1049-1052, doi:10.1038/nature06211 (2007).
1839 191 Takeichi, M. Dynamic contacts: rearranging adherens junctions to drive epithelial
1840 remodelling. *Nat Rev Mol Cell Biol* **15**, 397-410, doi:10.1038/nrm3802 (2014).
1841 192 Harris, T. J. C. Sculpting epithelia with planar polarized actomyosin networks:
1842 Principles from Drosophila. *Semin Cell Dev Biol* **81**, 54-61,
1843 doi:10.1016/j.semcdb.2017.07.042 (2018).
1844 193 Pare, A. C. & Zallen, J. A. Cellular, molecular, and biophysical control of epithelial
1845 cell intercalation. *Curr Top Dev Biol* **136**, 167-193,
1846 doi:10.1016/bs.ctdb.2019.11.014 (2020).
1847 194 Truong Quang, B. A., Mani, M., Markova, O., Lecuit, T. & Lenne, P. F. Principles of
1848 E-cadherin supramolecular organization in vivo. *Curr Biol* **23**, 2197-2207,
1849 doi:10.1016/j.cub.2013.09.015 (2013).
1850 195 Levayer, R., Pelissier-Monier, A. & Lecuit, T. Spatial regulation of Dia and Myosin-
1851 II by RhoGEF2 controls initiation of E-cadherin endocytosis during epithelial
1852 morphogenesis. *Nat Cell Biol* **13**, 529-540, doi:10.1038/ncb2224 (2011).
1853 196 Pope, K. L. & Harris, T. J. Control of cell flattening and junctional remodeling
1854 during squamous epithelial morphogenesis in Drosophila. *Development* **135**,
1855 2227-2238, doi:10.1242/dev.019802 (2008).
1856 197 Cavanaugh, K. E., Staddon, M. F., Munro, E., Banerjee, S. & Gardel, M. L. RhoA
1857 Mediates Epithelial Cell Shape Changes via Mechanosensitive Endocytosis. *Dev*
1858 *Cell*, doi:10.1016/j.devcel.2019.12.002 (2019).
1859 **This study (together with work by Sumi et al. (2018)) illustrates how the**
1860 **pulsating activity of RHOA-mediated contractility, in model epithelial tissues,**
1861 **leads to fluctuation in junctional length, and that the shortening of the junction**
1862 **requires formin-mediated E-cadherin clustering and dynamin-dependent**
1863 **endocytosis.**
1864 198 Sumi, A. *et al.* Adherens Junction Length during Tissue Contraction Is Controlled
1865 by the Mechanosensitive Activity of Actomyosin and Junctional Recycling. *Dev*
1866 *Cell* **47**, 453-463 e453, doi:10.1016/j.devcel.2018.10.025 (2018).

Shows that during amnioserosa contraction in *D. melanogaster*, adherens junctions reduce their length in coordination with the shrinkage of apical cell area, maintaining a nearly constant junctional straightness, which is ensured by the endocytic machinery that removes excess plasma membrane.

199 Miao, H., Vanderleest, T. E., Jewett, C. E., Loerke, D. & Blankenship, J. T. Cell ratcheting through the Sbf RabGEF directs force balancing and stepped apical constriction. *J Cell Biol* **218**, 3845-3860, doi:10.1083/jcb.201905082 (2019).

200 Jewett, C. E. *et al.* Planar polarized Rab35 functions as an oscillatory ratchet during cell intercalation in the Drosophila epithelium. *Nat Commun* **8**, 476, doi:10.1038/s41467-017-00553-0 (2017).

By examining RAB protein distributions during cell intercalation in *D. melanogaster* epithelial tissue remodelling, RAB35-mediated endocytosis of plasma membrane at junctions is found to serve as a unique ratcheting device that directs progressive interface contraction.

201 Kouranti, I., Sachse, M., Arouche, N., Goud, B. & Echard, A. Rab35 regulates an endocytic recycling pathway essential for the terminal steps of cytokinesis. *Curr Biol* **16**, 1719-1725, doi:10.1016/j.cub.2006.07.020 (2006).

202 Corallino, S. *et al.* A RAB35-p85/PI3K axis controls oscillatory apical protrusions required for efficient chemotactic migration. *Nat Commun* **9**, 1475, doi:10.1038/s41467-018-03571-8 (2018).

Demonstration that RAB35 plays a critical role in regulating the formation of oscillatory, apical circular ruffles that act as steering devices during chemotaxis and promote efficient migration and invasion in breast cancer.

203 Wheeler, D. B., Zoncu, R., Root, D. E., Sabatini, D. M. & Sawyers, C. L. Identification of an oncogenic RAB protein. *Science* **350**, 211-217, doi:10.1126/science.aaa4903 (2015).

204 Shaughnessy, R. & Echard, A. Rab35 GTPase and cancer: Linking membrane trafficking to tumorigenesis. *Traffic* **19**, 247-252, doi:10.1111/tra.12546 (2018).

205 Rainero, E. Extracellular matrix internalization links nutrient signalling to invasive migration. *Int J Exp Pathol* **99**, 4-9, doi:10.1111/iep.12265 (2018).

206 Yong, C. Q. Y. & Tang, B. L. Cancer-driving mutations and variants of components of the membrane trafficking core machinery. *Life Sci* **264**, 118662, doi:10.1016/j.lfs.2020.118662 (2021).

207 Bendris, N. & Schmid, S. L. Endocytosis, Metastasis and Beyond: Multiple Facets of SNX9. *Trends Cell Biol* **27**, 189-200, doi:10.1016/j.tcb.2016.11.001 (2017).

208 Bisi, S. *et al.* Membrane and actin dynamics interplay at lamellipodia leading edge. *Curr Opin Cell Biol* **25**, 565-573, doi:10.1016/j.ceb.2013.04.001 (2013).

209 Caswell, P. T., Vadrevu, S. & Norman, J. C. Integrins: masters and slaves of endocytic transport. *Nat Rev Mol Cell Biol* **10**, 843-853, doi:10.1038/nrm2799 (2009).

210 De Franceschi, N., Hamidi, H., Alanko, J., Sahgal, P. & Ivaska, J. Integrin traffic - the update. *J Cell Sci* **128**, 839-852, doi:10.1242/jcs.161653 (2015).

211 Montell, D. J., Yoon, W. H. & Starz-Gaiano, M. Group choreography: mechanisms orchestrating the collective movement of border cells. *Nat Rev Mol Cell Biol* **13**, 631-645, doi:10.1038/nrm3433 (2012).

1912 212 Cheung, K. J. *et al.* Polyclonal breast cancer metastases arise from collective
1913 dissemination of keratin 14-expressing tumor cell clusters. *Proc Natl Acad Sci U S*
1914 *A* **113**, E854-863, doi:10.1073/pnas.1508541113 (2016).
1915 213 Cheung, K. J., Gabrielson, E., Werb, Z. & Ewald, A. J. Collective invasion in breast
1916 cancer requires a conserved basal epithelial program. *Cell* **155**, 1639-1651,
1917 doi:10.1016/j.cell.2013.11.029 (2013).
1918 214 Hakim, V. & Silberzan, P. Collective cell migration: a physics perspective. *Rep*
1919 *Prog Phys* **80**, 076601, doi:10.1088/1361-6633/aa65ef (2017).
1920 215 Tambe, D. T. *et al.* Collective cell guidance by cooperative intercellular forces.
1921 *Nat Mater* **10**, 469-475, doi:10.1038/nmat3025 (2011).
1922 216 Peglion, F., Llense, F. & Etienne-Manneville, S. Adherens junction treadmilling
1923 during collective migration. *Nat Cell Biol* **16**, 639-651, doi:10.1038/ncb2985
1924 (2014).
1925 217 Theveneau, E. & Mayor, R. Neural crest delamination and migration: from
1926 epithelium-to-mesenchyme transition to collective cell migration. *Dev Biol* **366**,
1927 34-54, doi:10.1016/j.ydbio.2011.12.041 (2012).
1928 218 Lin, M. E., Herr, D. R. & Chun, J. Lysophosphatidic acid (LPA) receptors: signaling
1929 properties and disease relevance. *Prostaglandins Other Lipid Mediat* **91**, 130-
1930 138, doi:10.1016/j.prostaglandins.2009.02.002 (2010).
1931 219 Kuriyama, S. *et al.* In vivo collective cell migration requires an LPAR2-dependent
1932 increase in tissue fluidity. *J Cell Biol* **206**, 113-127, doi:10.1083/jcb.201402093
1933 (2014).
1934 220 Muinonen-Martin, A. J. *et al.* Melanoma cells break down LPA to establish local
1935 gradients that drive chemotactic dispersal. *PLoS Biol* **12**, e1001966,
1936 doi:10.1371/journal.pbio.1001966 (2014).
1937 221 Juin, A. *et al.* N-WASP Control of LPAR1 Trafficking Establishes Response to Self-
1938 Generated LPA Gradients to Promote Pancreatic Cancer Cell Metastasis. *Dev Cell*
1939 **51**, 431-445 e437, doi:10.1016/j.devcel.2019.09.018 (2019).
1940 **Demonstration that the promoter of actin nucleation, N-WASP (WASL), drives**
1941 **the trafficking of LPA receptors to control cellular responses to self-generated**
1942 **gradients and to enhance metastatic spreading of pancreatic ductal**
1943 **carcinomas.**
1944 222 Leyton-Puig, D. *et al.* Flat clathrin lattices are dynamic actin-controlled hubs for
1945 clathrin-mediated endocytosis and signalling of specific receptors. *Nat Commun*
1946 **8**, 16068, doi:10.1038/ncomms16068 (2017).
1947 223 Park, J. A. *et al.* Unjamming and cell shape in the asthmatic airway epithelium.
1948 *Nat Mater* **14**, 1040-1048, doi:10.1038/nmat4357 (2015).
1949 **A seminal paper showing the physical principles governing the transition from**
1950 **a solid, jammed to a collectively-moving and unjammed pseudostratified**
1951 **human bronchial epithelial system from asthmatic patients.**
1952 224 Sadati, M., Nourhani, A., Fredberg, J. J. & Taheri Qazvini, N. Glass-like dynamics
1953 in the cell and in cellular collectives. *Wiley Interdiscip Rev Syst Biol Med* **6**, 137-
1954 149, doi:10.1002/wsbm.1258 (2014).
1955 225 Sadati, M., Taheri Qazvini, N., Krishnan, R., Park, C. Y. & Fredberg, J. J. Collective
1956 migration and cell jamming. *Differentiation* **86**, 121-125,
1957 doi:10.1016/j.diff.2013.02.005 (2013).

1958 226 Park, J. A., Atia, L., Mitchel, J. A., Fredberg, J. J. & Butler, J. P. Collective migration
1959 and cell jamming in asthma, cancer and development. *J Cell Sci* **129**, 3375-3383,
1960 doi:10.1242/jcs.187922 (2016).
1961 227 Atia, L. *et al.* Geometric constraints during epithelial jamming. *Nat Phys* **14**, 613-
1962 620, doi:10.1038/s41567-018-0089-9 (2018).
1963 228 Bi, D., Yang, X., Marchetti, M. C. & Manning, M. L. Motility-Driven Glass and
1964 Jamming Transitions in Biological Tissues. *Physical Review X* **6**, 021011 (2016).
1965 229 Garcia, S. *et al.* Physics of active jamming during collective cellular motion in a
1966 monolayer. *Proc Natl Acad Sci U S A* **112**, 15314-15319,
1967 doi:10.1073/pnas.1510973112 (2015).
1968 230 de Beco, S., Amblard, F. & Coscoy, S. New insights into the regulation of E-
1969 cadherin distribution by endocytosis. *International review of cell and molecular*
1970 *biology* **295**, 63-108, doi:10.1016/B978-0-12-394306-4.00008-3 (2012).
1971 231 Palamidessi, A. *et al.* Unjamming overcomes kinetic and proliferation arrest in
1972 terminally differentiated cells and promotes collective motility of carcinoma. *Nat*
1973 *Mater* **18**, 1252-1263, doi:10.1038/s41563-019-0425-1 (2019).
1974 232 Ilina, O. *et al.* Cell-cell adhesion and 3D matrix confinement determine jamming
1975 transitions in breast cancer invasion. *Nat Cell Biol* **22**, 1103-1115,
1976 doi:10.1038/s41556-020-0552-6 (2020).
1977 **In this work the authors show that cell crowding induced by matrix**
1978 **confinement and cell–cell adhesion modulate the jamming transition during**
1979 **breast cancer invasion.**
1980 233 Mongera, A. *et al.* A fluid-to-solid jamming transition underlies vertebrate body
1981 axis elongation. *Nature* **561**, 401-405, doi:10.1038/s41586-018-0479-2 (2018).
1982 234 Mitchel, J. A. *et al.* In primary airway epithelial cells, the unjamming transition is
1983 distinct from the epithelial-to-mesenchymal transition. *Nat Commun* **11**, 5053,
1984 doi:10.1038/s41467-020-18841-7 (2020).
1985 235 Greenburg, G. & Hay, E. D. Epithelia suspended in collagen gels can lose polarity
1986 and express characteristics of migrating mesenchymal cells. *J Cell Biol* **95**, 333-
1987 339, doi:10.1083/jcb.95.1.333 (1982).
1988 236 Nieto, M. A., Huang, R. Y., Jackson, R. A. & Thiery, J. P. Emt: 2016. *Cell* **166**, 21-45,
1989 doi:10.1016/j.cell.2016.06.028 (2016).
1990 237 Aiello, N. M. & Kang, Y. Context-dependent EMT programs in cancer metastasis. *J*
1991 *Exp Med* **216**, 1016-1026, doi:10.1084/jem.20181827 (2019).
1992 238 Bakir, B., Chiarella, A. M., Pitarresi, J. R. & Rustgi, A. K. EMT, MET, Plasticity, and
1993 Tumor Metastasis. *Trends Cell Biol* **30**, 764-776, doi:10.1016/j.tcb.2020.07.003
1994 (2020).
1995 239 Pastushenko, I. & Blanpain, C. EMT Transition States during Tumor Progression
1996 and Metastasis. *Trends Cell Biol* **29**, 212-226, doi:10.1016/j.tcb.2018.12.001
1997 (2019).
1998 240 Dongre, A. & Weinberg, R. A. New insights into the mechanisms of epithelial-
1999 mesenchymal transition and implications for cancer. *Nat Rev Mol Cell Biol* **20**, 69-
2000 84, doi:10.1038/s41580-018-0080-4 (2019).
2001 241 Mani, S. A. *et al.* The epithelial-mesenchymal transition generates cells with
2002 properties of stem cells. *Cell* **133**, 704-715, doi:10.1016/j.cell.2008.03.027 (2008).
2003 242 van Staalduinen, J., Baker, D., Ten Dijke, P. & van Dam, H. Epithelial-
2004 mesenchymal-transition-inducing transcription factors: new targets for tackling

2005 chemoresistance in cancer? *Oncogene* **37**, 6195-6211, doi:10.1038/s41388-018-
2006 0378-x (2018).
2007 243 Shibue, T. & Weinberg, R. A. EMT, CSCs, and drug resistance: the mechanistic link
2008 and clinical implications. *Nat Rev Clin Oncol* **14**, 611-629,
2009 doi:10.1038/nrclinonc.2017.44 (2017).
2010 244 Corallino, S., Malabarba, M. G., Zobel, M., Di Fiore, P. P. & Scita, G. Epithelial-to-
2011 Mesenchymal Plasticity Harnesses Endocytic Circuitries. *Front Oncol* **5**, 45,
2012 doi:10.3389/fonc.2015.00045 (2015).
2013 245 Yang, J. *et al.* Guidelines and definitions for research on epithelial-mesenchymal
2014 transition. *Nat Rev Mol Cell Biol* **21**, 341-352, doi:10.1038/s41580-020-0237-9
2015 (2020).
2016 246 Stemmler, M. P., Eccles, R. L., Brabletz, S. & Brabletz, T. Non-redundant functions
2017 of EMT transcription factors. *Nat Cell Biol* **21**, 102-112, doi:10.1038/s41556-018-
2018 0196-y (2019).
2019 247 Skrypek, N., Goossens, S., De Smedt, E., Vandamme, N. & Berx, G. Epithelial-to-
2020 Mesenchymal Transition: Epigenetic Reprogramming Driving Cellular Plasticity.
2021 *Trends Genet* **33**, 943-959, doi:10.1016/j.tig.2017.08.004 (2017).
2022 248 Lamouille, S., Xu, J. & Derynck, R. Molecular mechanisms of epithelial-
2023 mesenchymal transition. *Nat Rev Mol Cell Biol* **15**, 178-196,
2024 doi:10.1038/nrm3758 (2014).
2025 249 Pastushenko, I. *et al.* Identification of the tumour transition states occurring
2026 during EMT. *Nature* **556**, 463-468, doi:10.1038/s41586-018-0040-3 (2018).
2027 **The first in vivo demonstration that, in tumours, subpopulations can be**
2028 **identified which exhibit all different EMT stages, from epithelial to**
2029 **mesechymal, through intermediate different hybrid states.**
2030 250 Aiello, N. M. *et al.* EMT Subtype Influences Epithelial Plasticity and Mode of Cell
2031 Migration. *Dev Cell* **45**, 681-695 e684, doi:10.1016/j.devcel.2018.05.027 (2018).
2032 **Through an in vivo approach, in a mouse model of pancreatic ductal**
2033 **adenocarcinoma, it is shown that EMT can proceed through endocytosis rather**
2034 **than transcriptional reprogramming, leading to a partial EMT phenotype.**
2035 251 Reichert, M. *et al.* Regulation of Epithelial Plasticity Determines Metastatic
2036 Organotropism in Pancreatic Cancer. *Dev Cell* **45**, 696-711 e698,
2037 doi:10.1016/j.devcel.2018.05.025 (2018).
2038 **By using several mouse models of pancreatic ductal adenocarcinoma, the**
2039 **authors show that the organotropic metastatic preference is a function of the**
2040 **degree of EMT (full blown EMT *vs*. partial EMT).**
2041 252 Vieira, A. V., Lamaze, C. & Schmid, S. L. Control of EGF receptor signaling by
2042 clathrin-mediated endocytosis. *Science* **274**, 2086-2089,
2043 doi:10.1126/science.274.5295.2086 (1996).
2044 253 Khan, M. N., Savoie, S., Bergeron, J. J. & Posner, B. I. Characterization of rat liver
2045 endosomal fractions. In vivo activation of insulin-stimulable receptor kinase in
2046 these structures. *J Biol Chem* **261**, 8462-8472 (1986).
2047 254 Lai, W. H., Cameron, P. H., Doherty, J. J., 2nd, Posner, B. I. & Bergeron, J. J.
2048 Ligand-mediated autophosphorylation activity of the epidermal growth factor
2049 receptor during internalization. *J Cell Biol* **109**, 2751-2760,
2050 doi:10.1083/jcb.109.6.2751 (1989).

2051 255 Scita, G. & Di Fiore, P. P. The endocytic matrix. *Nature* **463**, 464-473,
2052 doi:10.1038/nature08910 (2010).
2053 256 Clevers, H. Modeling Development and Disease with Organoids. *Cell* **165**, 1586-
2054 1597, doi:10.1016/j.cell.2016.05.082 (2016).
2055 257 Mayle, K. M., Le, A. M. & Kamei, D. T. The intracellular trafficking pathway of
2056 transferrin. *Biochim Biophys Acta* **1820**, 264-281,
2057 doi:10.1016/j.bbagen.2011.09.009 (2012).
2058 258 Maurer, M. E. & Cooper, J. A. The adaptor protein Dab2 sorts LDL receptors into
2059 coated pits independently of AP-2 and ARH. *J Cell Sci* **119**, 4235-4246,
2060 doi:10.1242/jcs.03217 (2006).
2061 259 Mishra, S. K. *et al.* Disabled-2 exhibits the properties of a cargo-selective
2062 endocytic clathrin adaptor. *EMBO J* **21**, 4915-4926, doi:10.1093/emboj/cdf487
2063 (2002).
2064 260 Mishra, S. K., Watkins, S. C. & Traub, L. M. The autosomal recessive
2065 hypercholesterolemia (ARH) protein interfaces directly with the clathrin-coat
2066 machinery. *Proc Natl Acad Sci U S A* **99**, 16099-16104,
2067 doi:10.1073/pnas.252630799 (2002).
2068 261 Morris, S. M. & Cooper, J. A. Disabled-2 colocalizes with the LDLR in clathrin-
2069 coated pits and interacts with AP-2. *Traffic* **2**, 111-123, doi:10.1034/j.1600-
2070 0854.2001.020206.x (2001).
2071 262 Tao, W., Moore, R., Meng, Y., Smith, E. R. & Xu, X. X. Endocytic adaptors Arh and
2072 Dab2 control homeostasis of circulatory cholesterol. *J Lipid Res* **57**, 809-817,
2073 doi:10.1194/jlr.M063065 (2016).
2074 263 He, G. *et al.* ARH is a modular adaptor protein that interacts with the LDL
2075 receptor, clathrin, and AP-2. *J Biol Chem* **277**, 44044-44049,
2076 doi:10.1074/jbc.M208539200 (2002).
2077 264 Beglova, N. & Blacklow, S. C. The LDL receptor: how acid pulls the trigger. *Trends
2078 Biochem Sci* **30**, 309-317, doi:10.1016/j.tibs.2005.03.007 (2005).
2079 265 Renard, H. F. *et al.* Endophilin-A2 functions in membrane scission in clathrin-
2080 independent endocytosis. *Nature* **517**, 493-496, doi:10.1038/nature14064
2081 (2015).
2082 266 Simunovic, M. *et al.* Friction Mediates Scission of Tubular Membranes Scaffolded
2083 by BAR Proteins. *Cell* **170**, 172-184 e111, doi:10.1016/j.cell.2017.05.047 (2017).
2084 267 Galperin, E. & Sorkin, A. Endosomal targeting of MEK2 requires RAF, MEK kinase
2085 activity and clathrin-dependent endocytosis. *Traffic* **9**, 1776-1790,
2086 doi:10.1111/j.1600-0854.2008.00788.x (2008).
2087 268 Pinilla-Macua, I., Watkins, S. C. & Sorkin, A. Endocytosis separates EGF receptors
2088 from endogenous fluorescently labeled HRas and diminishes receptor signaling
2089 to MAP kinases in endosomes. *Proc Natl Acad Sci U S A* **113**, 2122-2127,
2090 doi:10.1073/pnas.1520301113 (2016).
2091 269 Sigismund, S. *et al.* Threshold-controlled ubiquitination of the EGFR directs
2092 receptor fate. *EMBO J* **32**, 2140-2157, doi:10.1038/emboj.2013.149 (2013).
2093 270 Rochman, Y., Spolski, R. & Leonard, W. J. New insights into the regulation of T
2094 cells by gamma(c) family cytokines. *Nat Rev Immunol* **9**, 480-490,
2095 doi:10.1038/nri2580 (2009).

2096 271 Basquin, C. *et al.* Membrane protrusion powers clathrin-independent
2097 endocytosis of interleukin-2 receptor. *EMBO J* **34**, 2147-2161,
2098 doi:10.15252/embj.201490788 (2015).
2099 272 Grassart, A., Dujeancourt, A., Lazarow, P. B., Dautry-Varsat, A. & Sauvonnet, N.
2100 Clathrin-independent endocytosis used by the IL-2 receptor is regulated by Rac1,
2101 Pak1 and Pak2. *EMBO Rep* **9**, 356-362, doi:10.1038/embor.2008.28 (2008).
2102 273 Sauvonnet, N., Dujeancourt, A. & Dautry-Varsat, A. Cortactin and dynamin are
2103 required for the clathrin-independent endocytosis of gammac cytokine receptor.
2104 *J Cell Biol* **168**, 155-163, doi:10.1083/jcb.200406174 (2005).
2105 274 Blasky, A. J., Mangan, A. & Prekeris, R. Polarized protein transport and lumen
2106 formation during epithelial tissue morphogenesis. *Annu Rev Cell Dev Biol* **31**, 575-
2107 591, doi:10.1146/annurev-cellbio-100814-125323 (2015).
2108 275 Winter, J. F. *et al.* Caenorhabditis elegans screen reveals role of PAR-5 in RAB-11-
2109 recycling endosome positioning and apicobasal cell polarity. *Nat Cell Biol* **14**, 666-
2110 676, doi:10.1038/ncb2508 (2012).
2111 276 Apodaca, G., Gallo, L. I. & Bryant, D. M. Role of membrane traffic in the
2112 generation of epithelial cell asymmetry. *Nat Cell Biol* **14**, 1235-1243,
2113 doi:10.1038/ncb2635 (2012).
2114 277 Henry, L. & Sheff, D. R. Rab8 regulates basolateral secretory, but not recycling,
2115 traffic at the recycling endosome. *Mol Biol Cell* **19**, 2059-2068,
2116 doi:10.1091/mbc.E07-09-0902 (2008).
2117 278 Babbey, C. M. *et al.* Rab10 regulates membrane transport through early
2118 endosomes of polarized Madin-Darby canine kidney cells. *Mol Biol Cell* **17**, 3156-
2119 3175, doi:10.1091/mbc.e05-08-0799 (2006).
2120 279 Lock, J. G. & Stow, J. L. Rab11 in recycling endosomes regulates the sorting and
2121 basolateral transport of E-cadherin. *Mol Biol Cell* **16**, 1744-1755,
2122 doi:10.1091/mbc.e04-10-0867 (2005).
2123 280 Duman, J. G., Tyagarajan, K., Kolsi, M. S., Moore, H. P. & Forte, J. G. Expression of
2124 rab11a N124I in gastric parietal cells inhibits stimulatory recruitment of the H+-
2125 K+-ATPase. *Am J Physiol* **277**, C361-372, doi:10.1152/ajpcell.1999.277.3.C361
2126 (1999).
2127 281 Li, D., Mangan, A., Cicchini, L., Margolis, B. & Prekeris, R. FIP5 phosphorylation
2128 during mitosis regulates apical trafficking and lumenogenesis. *EMBO Rep* **15**,
2129 428-437, doi:10.1002/embr.201338128 (2014).
2130 282 Roland, J. T. *et al.* Rab GTPase-Myo5B complexes control membrane recycling
2131 and epithelial polarization. *Proc Natl Acad Sci U S A* **108**, 2789-2794,
2132 doi:10.1073/pnas.1010754108 (2011).
2133 283 Mendoza, M. C. *et al.* ERK-MAPK drives lamellipodia protrusion by activating the
2134 WAVE2 regulatory complex. *Mol Cell* **41**, 661-671,
2135 doi:10.1016/j.molcel.2011.02.031 (2011).
2136 284 Mendoza, M. C., Vilela, M., Juarez, J. E., Blenis, J. & Danuser, G. ERK reinforces
2137 actin polymerization to power persistent edge protrusion during motility. *Sci
2138 Signal* **8**, ra47, doi:10.1126/scisignal.aaa8859 (2015).
2139 285 Farooqui, R. & Fenteany, G. Multiple rows of cells behind an epithelial wound
2140 edge extend cryptic lamellipodia to collectively drive cell-sheet movement. *J Cell
2141 Sci* **118**, 51-63, doi:10.1242/jcs.01577 (2005).

2142 286 Giavazzi, F. *et al.* Flocking transitions in confluent tissues. *Soft Matter* **14**, 3471-
2143 3477, doi:10.1039/c8sm00126j (2018).
2144 287 Giavazzi, F. *et al.* Giant fluctuations and structural effects in a flocking
2145 epithelium. *Journal of Physics D: Applied Physics* **50**, 384003 (2017).
2146 288 Boucrot, E. & Kirchhausen, T. Endosomal recycling controls plasma membrane
2147 area during mitosis. *Proc Natl Acad Sci U S A* **104**, 7939-7944,
2148 doi:10.1073/pnas.0702511104 (2007).
2149 289 Tacheva-Grigorova, S. K., Santos, A. J., Boucrot, E. & Kirchhausen, T. Clathrin-
2150 mediated endocytosis persists during unperturbed mitosis. *Cell Rep* **4**, 659-668,
2151 doi:10.1016/j.celrep.2013.07.017 (2013).
2152 290 Aguet, F. *et al.* Membrane dynamics of dividing cells imaged by lattice light-sheet
2153 microscopy. *Mol Biol Cell* **27**, 3418-3435, doi:10.1091/mbc.E16-03-0164 (2016).
2154 291 Dix, C. L. *et al.* The Role of Mitotic Cell-Substrate Adhesion Re-modeling in
2155 Animal Cell Division. *Dev Cell* **45**, 132-145 e133,
2156 doi:10.1016/j.devcel.2018.03.009 (2018).
2157 292 Jones, M. C., Askari, J. A., Humphries, J. D. & Humphries, M. J. Cell adhesion is
2158 regulated by CDK1 during the cell cycle. *J Cell Biol* **217**, 3203-3218,
2159 doi:10.1083/jcb.201802088 (2018).
2160 293 Lock, J. G. *et al.* Reticular adhesions are a distinct class of cell-matrix adhesions
2161 that mediate attachment during mitosis. *Nat Cell Biol* **20**, 1290-1302,
2162 doi:10.1038/s41556-018-0220-2 (2018).
2163 **Mitotic matrix adhesion sites, termed 'reticular adhesions', are characterized in
2164 this study, showing that they are morphologically, dynamically and molecularly
2165 distinct from classical focal adhesions, being enriched in components of the
2166 clathrin machinery.**
2167 294 Zaidel-Bar, R. Atypical matrix adhesions guide cell division. *Nat Cell Biol* **20**, 1233-
2168 1235, doi:10.1038/s41556-018-0226-9 (2018).
2169 295 Elkhatib, N. *et al.* Tubular clathrin/AP-2 lattices pinch collagen fibers to support
2170 3D cell migration. *Science* **356**, doi:10.1126/science.aal4713 (2017).